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Abstract 
 
 
 Stimulation induced myosin RLC phosphorylation, catalyzed by the   
skeletal myosin light chain kinase (skMLCK) is known as the primary mechanism 
for twitch force potentiation (PTP). We assessed concentric PTP in the absence and 
presence of epinephrine  (1 μM).  To this end, extensor digitorum longus  (EDL)  
muscles   from wildtype  (WT)  and  skMLCK
-/-  
(KO)  mice  were  incubated  for  30-
minutes  in normal (CON) or epinephrine containing (EPI) Tyrode’s solution (in vitro, 
25°C); undergoing a series of twitches before and after a standard conditioning 
stimulus (CS; 4x100 Hz) to determine PTP (post-CS/pre-CS). Epinephrine initially 
enhanced PTP compared to the WT and KO control values, respectively; peaking at 
19.3 ± 1.6% and 15.7 ± 10.2% by the 8-minute mark (P < 0.0001) without altering 
myosin phosphorylation (P = 0.503). WT muscles were significantly elevated above 
KO values at all time points (P < 0.05); with the exception of the final 8-minute value 
(P = 0.172). However, both genotypes showed similar  responses  to  epinephrine  (r
2   
=  
0.895),  demonstrating  that  epinephrine may primarily act on a pathway independent of 
myosin phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
  
iii 
Acknowledgements 
Dr. Vandenboom 
I have you to thank for my growth as an academic, as well as an individual. Thank you 
for always pushing me to be my best and for believing in my abilities.  I will carry these 
lessons with me into whatever the future holds. 
My Supervisory Committee 
Thank you to Dr. LeBlanc and Dr. O’Leary for your tremendous input on this project. 
You have both worked to challenge me and encourage me to be more focused and driven; 
you have significantly improved the quality of work present. 
Fellow Lab Members and Classmates 
To those who have been there from the start, or have gone on to bigger things; I have all 
of you to thank for creating one of the most truly creative, open-minded, and inviting 
environments to spend the last two years. I have never been a part of such a cohesive 
group of driven individuals – there is no doubt you will all achieve greatness.  
Bill 
To say that all of this wouldn’t be possible without you would be an understatement. 
Thank you for being such an incredible mentor and friend. I hope nothing but the best for 
you and your family, and I know you will make a great father.  
Josh 
For as long as I’ve known you, I have always admired your drive and tenacity for hard 
work. I think that “3’rd year you” would be amazed with what you’ve been able to 
accomplish thus far, and that you will continue to do so. Don’t lose the things that have 
made you what you are, never stop moving forward. 
Jordan 
Thank you for always being someone that pushes me academically. As we move forward 
from this experience, I know that you’ll find nothing but success. You have the ability to 
do what you love, just don’t give up, it will come.  
 
 
 
 
  
iv 
To Those Reading 
If you are reading this document, then you are observing a defining point of my life. As 
such, I want to share with you something I have learned thus far. As far as I can tell, your 
own success is dependent on one person, as are your failures, and your will to move 
forward; that person is you. You are the key to achieving your dreams, and sometimes 
that will be a hard notion to maintain invested in. However, I promise you that if you do – 
you will end up where you want to be.  
Never be afraid to ask the tough questions, never be afraid to try something new, and 
never be afraid to fail; with that, you are ready for anything. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
v 
Table of Contents 
 
Abstract .............................................................................................................................. ii 
Acknowledgements .......................................................................................................... iii 
Table of Contents .............................................................................................................. v 
List of Abbreviations ..................................................................................................... viii 
List of Tables .................................................................................................................... ix 
List of Equations .............................................................................................................. ix 
List of Figures .................................................................................................................... x 
Introduction ....................................................................................................................... 1 
Review of Literature ......................................................................................................... 4 
2.0.0 Skeletal Muscle: The Contractile Apparatus ................................................................. 4 
2.1.0 Excitation Contraction Coupling (ECC) ........................................................................ 5 
2.2.0 Physiological Consequences: Myosin Light Chain Phosphorylation ........................... 7 
2.2.1 Potentiation in Skeletal Muscle ...................................................................................... 8 
2.2.2 Manifestation of Twitch Force Potentiation................................................................... 9 
2.2.3 Evidence From Knock-Out (skMLCK-/-) Models .......................................................... 11 
2.2.4 Contraction Type Dependence ..................................................................................... 12 
2.2.5 β-Agonists and Force Potentiation ............................................................................... 13 
2.2.6 β-Agonists and Mechanical Characteristics ................................................................ 15 
2.2.7 Temporal Twitch Parameters ....................................................................................... 15 
2.2.8 Proposed Mechanisms of Epinephrine ......................................................................... 16 
2.3.0 Sympathetic Nervous System & Adrenoceptors .......................................................... 19 
2.3.1 G-Protein Coupled Receptor Family (GPCRs) ............................................................ 21 
2.3.2 The β-Adrenoceptor ...................................................................................................... 22 
2.4.0 The β-adrenoceptor Agonist .......................................................................................... 26 
2.5.0 β-adrenoceptor signaling in skeletal muscle ................................................................. 28 
2.5.1 β2-Adrenoceptor Signaling of cAMP ............................................................................ 28 
2.6.0 The effects of β-adrenoceptor on skeletal muscle function ......................................... 30 
2.6.1 β2-Agonist on Skeletal Muscle Fiber Type, Force, and Force Development ............... 30 
2.6.2 β2-Agonist Molecular Signaling for Increased Force and The Role of Ca
2+: Proof 
From Genetic Knock-Out Mice ............................................................................................. 33 
Statement of The Problem .............................................................................................. 36 
3.1.0   Central Research Question .......................................................................................... 36 
3.2.0   Hypothesis ..................................................................................................................... 36 
3.3.0   Assumptions .................................................................................................................. 37 
Methods ............................................................................................................................ 38 
4.1.0   Wild-Type (WT) & skMLCK Knockout (KO) Mice ................................................. 38 
4.2.0   Experimental Apparatus .............................................................................................. 38 
4.3.0   Surgical Removal of EDL & Muscle Preparation ..................................................... 40 
4.4.0   Experimental Design .................................................................................................... 40 
4.4.1  Epinephrine Preparation ......................................................................................... 42 
4.4.2   Optimal Length ........................................................................................................... 43 
4.4.3   EDL Stimulation ......................................................................................................... 43 
4.4.4   Stimulation Profiles .................................................................................................... 44 
  
vi 
4.5.0   Calculation of Pre-Tetanic and Post-Tetanic Twitch Force ..................................... 44 
4.6.0   Peak Force Production ................................................................................................. 44 
4.7.0   Rate of Force Development (dF/dt) ............................................................................. 45 
4.8.0   Biochemical Analysis of Muscle Tissue ....................................................................... 45 
4.8.1 Quantitative Determination of Proteins: Bradford Assay ............................................ 45 
4.8.2 Gel Electrophoresis and Western Blotting ................................................................... 46 
4.9.0   Laboratory Procedures ................................................................................................ 48 
4.10.0 Data Analysis & Statistics ............................................................................................ 49 
Results .............................................................................................................................. 51 
5.1.0 Mouse Characteristics .................................................................................................... 51 
5.2.0 Contractile Measures...................................................................................................... 52 
5.2.1 Absolute Concentric Twitch Force ............................................................................... 52 
5.2.1.1 Within Genotype Analysis .................................................................................................. 52 
5.2.1.2 Between Genotype Analysis ............................................................................................... 52 
5.2.2 Relative Concentric Twitch Force: PTP ...................................................................... 53 
5.3.0 Effect of Epinephrine Treatment on Force and Post-tetanic Potentiation ................ 54 
5.3.1 Absolute Concentric Twitch Force ............................................................................... 54 
5.3.1.1 Within Genotype Analysis .................................................................................................. 54 
5.3.1.2 Between Genotype Analysis ............................................................................................... 55 
5.3.2 Relative Concentric Twitch Force: PTP ...................................................................... 56 
5.3.2.2 Between Genotype Analysis ............................................................................................... 60 
5.4.3 Concentric Twitch Kinetics .......................................................................................... 63 
5.5.0 Myosin RLC Phosphorylation ....................................................................................... 65 
Discussion ......................................................................................................................... 67 
6.1.0 General Summary of Results and Findings .................................................................. 67 
6.2.0 Relation to Previous Studies .......................................................................................... 68 
6.3.0 Contractile Mechanics of Wildtype and skMLCK-/- muscles ..................................... 69 
6.3.1 The Effect of PTP on Concentric Force ....................................................................... 69 
6.3.1.1 Wildtype Muscles ................................................................................................................ 69 
6.3.1.2 skMLCK-/- Muscles ............................................................................................................. 71 
6.4.0 Myosin RLC phosphorylation ....................................................................................... 73 
6.4.1 Ca2+ Based Mechanisms for Potentiation .................................................................... 79 
6.5.0 The Effect of Epinephrine on Force Production .......................................................... 81 
6.5.1 Inotropic Effects of Epinephrine .................................................................................. 81 
6.6.0 The Epinephrine-Induced Maintenance of Concentric PTP ...................................... 83 
6.7.0 Effect of Epinephrine on Twitch Kinetics .................................................................... 86 
6.7.1 Rate of Force Development (+dP/dt) and Time to Peak Tension (TPT) ...................... 86 
6.7.2 Rate of Relaxation (-dP/dt) and Half Relaxation Time (RT1/2) ..................................... 87 
6.8.0   Limitations .................................................................................................................... 89 
Conclusions and Significance ......................................................................................... 90 
7.1.0 Primary Findings ............................................................................................................ 90 
7.2.0 Significance of Findings ................................................................................................. 91 
7.3.0 Future Research & Considerations ............................................................................... 94 
References ........................................................................................................................ 95 
Appendix A: Tyrode’s Solution and Surgical Anaesthetic ....................................... 118 
Appendix B: Surgical Removal/EDL mounting ......................................................... 119 
Appendix C: Bradford Reagents ................................................................................. 121 
  
vii 
Appendix D: Urea/Glycerol-PAGE and Immunoblotting ......................................... 124 
Appendix E: Experiments Determining Optimal Loading Volume ......................... 131 
Appendix F: Western Blots and Values ...................................................................... 139 
Appendix G: Statistical Analysis ................................................................................. 141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
viii 
List of Abbreviations 
 
 
Ca2 + = Calcium  
CaM = Calcium-Calmodulin 
CON = Control Group 
CREB = cAMP response element-binding protein 
EDL = Extensor digitorum longus 
EPAC = Exchange protein activated by cAMP 
EPI = Epinephrine 
FoxO = forkhead transcription factor  
GB = B subunit of G protein 
Gai = inhibitory subunit of G protein 
Gas = Stimulatory subunit of G protein 
GY = Y subunit of G protein 
GSK = glycogen synthase kinase 
Lo = Optimal Muscle Length 
Po, Pt = Peak Tetanic Force, Peak Twitch Force 
PKA = cAMP dependent protein kinase A 
PTP = Post-Tetanic Twitch Potentiation 
RLC = Regulatory Light Chain 
skMLCK = Skeletal Muscle Myosin Light Chain Kinase 
skMLCP = Myosin Light Chain Phosphatase  
SR = Sarcoplasmic Reticulum 
Vmax, Vo = Maximal Shortening Velocity, Unloaded Shortening Velocity 
WT, KO = Wildtype, Knockout 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ix 
List of Tables 
 
TABLE 1. ADRENOCEPTOR SUBTYPES AND G PROTEINS; AKAP, A KINASE ANCHORING PROTEIN; AC, ADENYLYL 
CYCLASE; PKA, PROTEIN KINASE A.. ....................................................................................................... 25 
TABLE 2. THE REQUIRED INTRAVENOUS DOSE (ΜG/KG) FOR MINIMAL EFFECT OF EPINEPHRINE, NOREPINEPHRINE 
AND ISOPRENALINE IN THE TIBIALIS ANTERIOR AND SOLEUS. (BOWMAN AND ZAIMIS, 1958). ...................... 33 
TABLE 3. MEAN MASS FOR MICE USED IN BOTH CONTRACTILE AND BIOCHEMICAL EXPERIMENTS. ...................... 51 
TABLE 4.  THE EFFECT OF 1 ΜM EPINEPHRINE INCUBATION ON FORCE PRODUCTION AND PTP IN WILDTYPE AND 
SKMLCK-/- MOUSE EDL (25°C) ............................................................................................................. 59 
TABLE 5. THE DIFFERENCE IN CONCENTRIC FORCE POTENTIATION BETWEEN WILDTYPE AND SKMLCK-/- FOR 
BOTH CONTROL AND EPINEPHRINE TREATED EDL AT 25°C ..................................................................... 62 
TABLE 6. THE EFFECT OF 1 ΜM EPINEPHRINE INCUBATION ON CONCENTRIC TWITCH KINETICS IN WILDTYPE AND 
SKMLCK-/- MOUSE EDL AT 25°C ........................................................................................................... 64 
 
 
List of Equations 
 
 
EQUATION 1. CALCULATION FOR DETERMINING THE % PHOSPHORYLATION OF RLC PROTEIN BANDS. ......... 46 
EQUATION 2. THE DIFFERENCE BETWEEN PTP IN THE EPINEPHRINE CONDITION AND THE CONTROL 
CONDITION.. .......................................................................................................................................... 61 
EQUATION 3. THEORETICAL FRAMEWORK FOR CROSS-BRIDGES FOUND IN THE FORCE GENERATING STATE 
(ΑFS). ..................................................................................................................................................... 70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
x 
List of Figures 
 
 
FIGURE 1. MYOSIN FILAMENT, AND MYOSIN HEAD MICROANATOMY. ............................................................. 5 
FIGURE 2. VOLTAGE SENSOR-CONTROLLED CA2+ RELEASE IN SKELETAL MUSCLE .......................................... 6 
FIGURE 3. CYCLING OF CALCIUM BETWEEN SR AND CYTOPLASM ................................................................... 6 
FIGURE 4. CHANGE OF MYOSIN HEAD POSITION FROM WEAKLY BOUND TO STRONGLY BOUND STATE WITH 
RLC PHOSPHORYLATION ........................................................................................................................ 7 
FIGURE 5. AN EXAMPLE OF BOTH POST-TETANIC POTENTIATION (A) AND STAIRCASE POTENTIATION (B) IN 
FAST TWITCH SKELETAL MUSCLE UNDER TYPICAL EXPERIMENTAL PARADIGMS. MODIFIED FROM. ...... 10 
FIGURE 6. POTENTIAL MECHANISM OF ADRENALINE DURING POST-TETANIC ACTIVATION; INHIBITION OF 
SKMLCK. MODIFIED FROM STULL ET AL., (2011). ............................................................................... 18 
FIGURE 7. GΑS -, GΑI -, AND GΒΓ SIGNALING PATHWAYS IN SKELETAL MUSCLE, ALL ACTIVATED BY A Β2-
AGONIST STIMULATION VIA THE Β2-ADRENOCEPTOR. ........................................................................... 29 
FIGURE 8. A. EFFECT OF ISOPROTERENOL ON FORCE GENERATION IN WILDTYPE EDL; B. EFFECT OF 
ISOPRTERENOL ON PEAK FORCE IN WILDTYPE EDL; C. EFFECT OF ISOPROTERNOL ON FORCE 
GENERATION IN RYR1 MUTATED EDL; D. EFFECT OF ISOPROTERNOL ON PEAK FORCE IN RYR1 
MUTATED EDL. .................................................................................................................................... 35 
FIGURE 9. MHC EXPRESSION IN MOUSE EDL MUSCLE .................................................................................. 37 
FIGURE 10. ASI ORGAN BATH CONTAINING TYRODE’S SOLUTION FOR IN VITRO INTACT MUSCLE EXPERIMENT.
 ............................................................................................................................................................. 39 
FIGURE 11. EXPERIMENTAL GROUP DESIGN ................................................................................................. 41 
FIGURE 12. EXPERIMENTAL PROTOCOL ......................................................................................................... 42 
FIGURE 13. TITRATION OF THREE DIFFERENT EPINEPHRINE CONCENTRATIONS (1, 2, 3 UM) ON CONCENTRIC 
PTP TIME COURSE OF WILDTYPE EDL 25°C ......................................................................................... 43 
FIGURE 14. TOTAL, PASSIVE, AND ACTIVE FORCE TRACES OF A CONCENTRIC TWITCH (EDL)..................... 45 
FIGURE 15. IMAGES OF EACH STEP OF THE UREA/GLYCEROL-PAGE METHOD.. ............................................. 53 
FIGURE 17. RELATIVE PEAK CONCENTRIC TWITCH POTENTIATION (POST-CS/PRE-CS) OF WILDTYPE (A) AND 
SKMLCK-/- (B) CONTROL MUSCLES DURING 8-MINUTE EXPERIMENTAL TIME COURSE FOLLOWING HIGH-
FREQUENCY CONDITIONING STIMULUS. ................................................................................................ 65 
FIGURE 18. REPRESENTATIVE TRACE OF TETANIC FORCE (MN) IN WILDTYPE (A) AND SKMLCK-/- (B) 
EPINEPHRINE TREATED MUSCLES DURING THE CONDITIONING STIMULUS ............................................. 56 
FIGURE 19. EFFECT OF EPINEPHRINE ON CONCENTRIC TWITCH FORCE POTENTIATION AFTER A CS IN 
WILDTYPE (A) AND SKMLCK-/- (B) MOUSE EDL AT 25°C  .................................................................. 58 
FIGURE 20. RELATIVE DIFFERENCE IN TWITCH FORCE BETWEEN WILDTYPE AND SKMLCK-/- MUSCLES WITH 
AND WITHOUT EPINEPHRINE INCUBATION . ........................................................................................... 61 
FIGURE 21. ABSOLUTE PEAK CONCENTRIC TWITCH FORCE TRACES (MN) FROM WILDTYPE FROM SKMLCK-/- 
MUSCLES BEFORE (A), 5 SECONDS AFTER (B) AND 8 MINUTES AFTER (C) A CONDITIONING STIMULUS . 63 
FIGURE 22. THE EFFECT OF TIME AND EPINEPHRINE TREATMENT ON MYOSIN RLC PHOSPHORYLATION IN 
WILDTYPE EDL AT  REST, 5 SECONDS, AND 8 MINUTES ........................................................................ 65 
FIGURE 23. CROPPED IMAGES FROM APPENDIX F, UREA/GLYCEROL PAGE BLOTS OF MYOSIN LIGHT CHAIN 
PHOSPHATE CONTENT IN WILDTYPE (A) AND (B) SKMLCK-/- MUSCLES FROM BOTH CONTROL (CON) 
AND EPINEPHRINE (EPI) CONDITIONS.................................................................................................... 66 
FIGURE 24. SEPARATION OF NON-PHOSPHORYLATED (RLC) AND PHOSPHORYLATED (RLC-P) RLC BY 
UREA/GLYCEROL-PAGE. . .................................................................................................................... 76 
FIGURE 25. COLLISION-INDUCED FRAGMENTATION SPECTRUM ..................................................................... 77
  
1 
 
 
Introduction 
 
 
Mammalian skeletal muscle has unique roles in metabolism, thermogenesis, and 
most notably, locomotion. To help fulfill these roles, skeletal muscle is highly 
heterogeneous in nature, varying greatly in regard to muscle/fiber type (fast-type II vs. 
slow-type I) as well as neuronal innervation. The ability of muscle to perform mechanical 
work, i.e. while shortening against an external load, begins at the level of the sarcomere. 
The sarcomere is recognized as the functional unit of muscle, and as such is host to 
myriad actomyosin complexes responsible for muscle force, shortening, and work 
production. The actomyosin complex is composed of the two major contractile proteins, 
actin, and myosin. Variations in muscle motor performance and fiber type are 
intrinsically related to variations in myosin heavy chain (MyHC) isoform. For example, 
MyHC isoform differences in cross-bridge cycling probability, duty cycle and/or rate 
may account for differences in locomotion seen at the functional/animal level. One 
difference in this regard may be the posttranslational modification of myosin by 
phosphorylation of the regulatory light chain (RLC), a change that may modulate myosin 
motor function (Szczesna-Cordary, 2003; Sweeney et al., 1993) within the sarcomere and 
account for the phenomenon of potentiation. First observed over 100 years ago (Lee, 
1907), potentiation may be defined as the transient increase in isometric twitch force 
observed during or after muscle activity, and is now regarded as a fundamental property 
of fast twitch skeletal muscle function.  
Work performed on intact rodent and cat skeletal muscles showed that the 
application of a brief tetanic stimulation increased isometric twitch force independent of 
  
2 
change to peak tetanic force; thus potentiation increased the twitch to tetanus ratio 
(Bagust et al., 1974). The fact that similar observations have been made in frog skeletal 
muscle fibers (Ramsey & Street, 1941) demonstrates that the molecular origin for this so-
called “post-tetanic potentiation” was intrinsic to the muscle cell, and perhaps the 
sarcomere, itself. Indeed, subsequent biochemical work performed on mouse and rat 
skeletal muscle has shown that post-tetanic potentiation (PTP) is temporally correlated 
with the phosphorylation of the myosin regulatory light chain (RLC). For example, as 
identified by Vandenboom et al. (2013) robust correlations have been obtained between 
the extent of RLC phosphorylation and the magnitude of PTP in both rat and mouse fast 
twitch skeletal muscle within the temperature range 15 - 35° C (Klug et al. 1982; 
Manning and Stull, 1979; 1982; Moore and Stull, 1984; Moore et al., 1990; Palmer and 
Moore, 1989; Vandenboom et al 1995; 1997). Zhi et al. (2005) was the first to provide 
evidence that these correlations may also represent causality through fast twitch muscles 
from mice devoid of the ability to phosphorylate the RLC; they also did not exhibit PTP. 
This finding was later confirmed by Gittings et al. (2011). Thus, although this does not 
exclude other mechanisms, it appears that the RLC phosphorylation mechanism is 
responsible for some or most of for the PTP displayed by mammalian fast twitch skeletal 
muscle.  
The catalytic activity of myosin light chain kinase (skMLCK) is opposed by the 
myosin RLC phosphatase (skMLCP) and thus it is the balance between the activities of 
skMLCK and skMLCP which will determine net phosphorylation of the myosin RLC. 
Although a considerable amount has been learned regarding the advantage of isometric 
twitch force potentiation, there is still much that remains to be learned regarding how 
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potentiation influences overall organismal function (Vandenboom, 2013), for example the 
influence of -agonists in dynamic models of potentiation. One major consideration is the 
influence of intact extra-cellular signaling and it’s affect on potentiation. Recent work by 
Decostre et al. (2000) shows that β-adrenergic stimulation prolongs the potentiated state 
and alters twitch kinetics and characteristics in isolated mouse fast muscle. These 
outcomes implicate a role for potentiation during the sympathetic fight-or-flight response 
of mammals. To date, no conclusions have been reached regarding how adrenaline causes 
this prolongation of twitch potentiation, however it has been hypothesized that adrenaline 
inhibits skMLCP through the phosphorylation of inhibitor-1 (I-1). Decostre et al. (2000) 
indicated that after 300 seconds (normal time course for potentiation dissipation) myosin 
phosphorylation was maintained (0.51 mol P/mol LC2) in the EPI condition, a value that 
was significantly higher than the controls (0.31 mol P/mol LC2), however there was no 
significant effect on the RLC phosphorylation or isometric twitch force in resting muscle. 
In addition, the prolongation of twitch potentiation was observed as long as RLC 
phosphorylation was elevated. The evidence presented primarily by Decostre et al. (2000) 
suggest a prolongation of myosin phosphorylation in the presence of adrenaline, however 
this effect may not be mediated via skMLCK as myosin phosphorylation was not 
increased with adrenaline incubation (Manning & Stull, 1982; Decostre et al., 2000). In 
addition, although these researchers observed increases in resting [Ca2+] and peak [Ca2+] 
transient both with and without adrenaline, these values returned to normal after 300 
seconds, giving even more support for MLCP as adrenalines mechanistic pathway. Thus, 
adrenergic stimulation may not increase phosphorylation of RLC per se but may slow the 
reduction in RLC phosphorylation via inhibition of skMLCP.  
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Review of Literature 
2.0.0 Skeletal Muscle: The Contractile Apparatus 
 From an idea as big as that of locomotion, to that of a much more isolated nature, 
all skeletal muscle relies on the same contractile anatomy to carry out it’s function. This 
function, at its core, is to convert stored chemical energy (ATP) into mechanical energy. 
This generation of muscular force is reliant on the constituent parts of its system, in this 
case, specialized proteins of actin and myosin. It is the interaction between these two 
proteins, which gives life to the sliding filament theory (Hanson & Huxley, 1953; Huxley 
& Hanson, 1954; Huxley, 1957). This concept stipulates that chemically driven power 
strokes of the myosin protein result in mechanical work, producing force. Each unit of the 
contractile apparatus in a muscle fiber is composed of the actin (thin) and myosin (thick) 
myofilaments. The actin filament is helical in structure, and is composed of 7 actin 
molecules as well as troponin (Tn) and tropomyosin (Tm). (Gordon, Homsher, & 
Regnier, 2000). The myosin filament (Figure 1) on the other hand consists of two heavy 
chains, and two pairs of light chains (ELC, essential light chain; RLC, regulatory light 
chain). Actin is anchored to each end of the functional unit (sarcomere) while myosin is 
in the center of each unit, held in position by the structural protein of titin. Stimulation of 
this functional unit results in the myosin head ‘pulling’ the actin filament towards its 
center (Huxley, 1957; 1969).   
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Figure 1. Myosin filament, and myosin head microanatomy (Rayment et al., 1993; Warrick & 
Spaudich, 1987).   
2.1.0 Excitation Contraction Coupling (ECC)  
 
In vertebrate skeletal muscle, force development is not only reliant on the 
contractile apparatus, and in fact this machinery is contingent upon a much larger control 
of [Ca2+] regulation in the cytoplasm. This regulation is a feature of the excitation-
contraction coupling (ECC) mechanism native to skeletal muscle. ECC begins with an 
action potential passing along the surface membrane and into a network of t-tubules 
(Lamb, 2000). This action potential results in depolarization, which is detected by 
dihydropyridine receptor (DHPR) molecules, also known as voltage-sensors (Schneider, 
1994; Melzer, Herrmann-Frank, & Luttgau, 1995) allowing for a way to directly activate 
the Ca2+ -release channels (RyR1) in the adjacent sarcoplasmic reticulum (SR) seen in 
Figure 2. 
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Figure 2. Voltage sensor-controlled Ca2+ release in skeletal muscle (Lamb, 2000) 
 
 Upon activation, the SR will release Ca2+ via these RyR1 channels, and flood the 
cytoplasm with calcium, so much so that the resting level of ~50nM (Berchtold, 
Brinkmeier, & Muntener, 2000) will be elevated ~100 fold. Upon release, this cytosolic 
calcium will rapidly bind to TnC and activate contraction by allowing myosin to bind to 
the active sites of actin, before being completely pumped back into the SR via SERCA 
protein pumps (Ca2+ ATPase), this cycle can be seen in Figure 3. 
 
 
Figure 3. Cycling of calcium between SR and cytoplasm (Berchtold, Brinkmeier, & Muntener, 
2000) 
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2.2.0 Physiological Consequences: Myosin Regulatory Light Chain Phosphorylation 
The RLC is important for both the structure and function of the myosin head 
during muscle contraction, it’s region of the myosin heavy chain (Figure 1) can undergo 
conformational changes, important for working muscle (Rayment et al, 1993; Uyeda, & 
Spudich, 1993). The RLCs role in contraction has been studied using in vitro motility 
assays, which show that the removal of RLC will result in reduced velocity of actin 
movement (Lowey, Waller, & Trybus, 1993), an observation that was reversible with the 
reconstitution of the myosin RLC.  
 
Figure 4. Change of myosin head position from weakly bound to strongly bound state with RLC 
phosphorylation (Szczesna-Cordary, 2003). 
 
 Section 2.1.0 outlines the effects of calcium regulation on contraction via TnC, 
however another destination for calcium after release from the SR is Ca2+/CaM. When 
calcium binds with the CaM (Calmodulin) the result is an activation of skMLCK, which 
causes phosphorylation of the RLC. The effects of RLC phosphorylation in intact rabbit 
skeletal muscle have been studied in vivo, showing that tetanic stimulation significantly 
elevates RLC phosphorylation (Moore et al. 1985). The major physiological outcomes of 
RLC phosphorylation have been demonstrated to be a change of Ca2+ sensitivity of force 
development (Metzger, Greaser, & Moss, 1989; Sweeney, Bowman, & Stull, 1993; 
Szczensa et al, 2002) as well as a raise in maximal steady state force (Szczensa et al, 
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2002). The structural connection between the phosphorylation of the RLC and the 
outcome of potentiated force is most likely a result of the recruitment of more strongly 
bound cross-bridges (Sweeney, Bowman, & Stull, 1993) because RLC phosphorylation 
causes the myosin head to move away from it’s thick filament backbone and become 
more accessible to actin. This was demonstrated using electron micrographs of skinned 
rabbit fibers, which lost their periodic arrangement of the relaxed state with the 
phosphorylation of RLC (Yang et al, 1998), a change that most likely reflects a change in 
charge due to phosphorylation, increasing myosin head mobility and accessibility to 
actin.  In terms of outcome, this means that a phosphorylation induced change in position 
of the myosin head may be responsible for increasing the number of cross-bridges 
involved in cycling, through up regulation of actin-induced phosphate release (Davis, 
Satorius, & Epstein, 2002) i.e. transitioning from the weakly bound to the strongly bound 
state. 
2.2.1 Potentiation in Skeletal Muscle 
 
Force potentiation has been documented as a fundamental characteristic of fast 
skeletal muscle first seen in literature over 100 years ago (Lee, 1907). Potentiation is 
usually observed as a transient increase in isometric twitch force, which has been 
observed independent of alteration to peak tetanic force (Bagust et al, 1974). The earliest 
work to show this phenomenon was performed on intact rodent and cat skeletal muscle 
(Brown & von Euler, 1938; Standaert, 1964), however similar findings in frog skeletal 
muscle fibers (Ramsey & Street, 1941) demonstrated that this isometric force potentiation 
is not species dependent, and is intrinsic to the muscle cell itself. More recent work 
showed that which potentiation in rodent muscle is strongly associated with myosin 
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regulatory light chain (RLC) phosphorylation. In fact, as Vandenboom et al. (2013) 
demonstrated, isometric twitch potentiation is temporally correlated with RLC 
phosphorylation after different types of conditioning stimuli. Although, studies which 
have multiple measurements of isometric twitch potentiation and RLC phosphorylation 
produced both non-linear (Klug et al., 1982) and linear relationships (Manning and Stull 
1979; Moore et al., 1990; Palmer and Moore 1989; Vandenboom et al., 1995, 1997; Xeni 
et al., 2011), these show a consistent relationship between RLC phosphorylation and 
potentiation. Thus, there is a direct and predictable influence of RLC phosphorylation on 
the isometric twitch force of fast twitch skeletal muscle; although this effect increases as 
temperature approaches the physiological range, temperature is just one of many factors 
that will affect the magnitude and duration of potentiation with other notable influences 
being muscle length (short > long), fiber type (IIb > Ia), contraction type (concentric > 
isometric), and stimulation paradigm. In addition, Gittings et al, (2012) demonstrated 
potentiation is shortening speed dependent, such that faster muscle speeds of shortening, 
produced increased potentiation.  
2.2.2 Manifestation of Twitch Force Potentiation 
 
There are two main types of potentiation: staircase potentiation and post-tetanic 
potentiation. Staircase potentiation refers to a progressive increase in isometric twitch 
force during low frequency stimulation (e.g., 10 Hz over 30 seconds), while the second 
type, post-tetanic potentiation (PTP) refers to a step-like increase in isometric twitch 
force, seen after a brief bout of high frequency stimulation (e.g., 150 Hz over 1 second). 
An example paradigm for both of these manifestations can be found in Figure 5. When 
staircase potentiation is elicited, one may see a decreased isometric twitch force before 
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seeing an eventual rise to a new peak. Under this condition, the peak amplitude depends 
on both stimulus rate and number. Potentiated twitch force will deteriorate when 
stimulation is stopped, slowly at first before deteriorating more rapidly (Krarup, 1981a). 
Alternatively, PTP yields an acute increase in isometric twitch force in response to a high 
(Close and Hoh, 1968b) or low-frequency stimulus. Just like staircase potentiation, PTP 
is reliant on both stimulus frequency, as well as duration. During PTP paradigm, twitch 
force displays an initial increase to a peak shortly after stimulation before rapidly, then 
slowly, dissipating over the course of several minutes (Krarup, 1981a). An example of 
stair case potentiation over a 60 second time course, and PTP over a 600 second time 
course can be found in Figure 5. 
 
Figure 5. An example of both post-tetanic potentiation (a) and staircase potentiation (b) in fast 
twitch skeletal muscle under typical experimental paradigms. Modified from (Vandenboom et al. 
2013). 
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 Evidence from skinned (or permeabilized) fibers was the first model to provide 
mechanistic evidence that RLC phosphorylation increased force. For example, Persechini 
et al. (1985) showed that the addition of skMLCK both increased phosphorylation of the 
RLC (0.10 mol P/ mol LC to 0.80 mol P/mol LC) and increased steady-state tension at 
submaximal Ca2+ activation of rabbit psoas fibers, however maximal force was not 
increased. Later work described how RLC phosphorylation-induced potentiation of 
steady state force was inversely associated to actin activation levels (Davis et al., 2002; 
Metzger et al., 1989; Patel et al., 1996, 1998; Szczesna et al., 2002). This finding 
provided an important mechanistic link between the skMLCK-catalyzed phosphorylation 
of RLC and twitch force potentiation. While it wasn’t until the 1970’s that skMLCK was 
recognized for it’s action on the RLC (Figure 4) as well as a role in Ca2+ activation, the 
first identification of the kinase was by Pires et al. (1974) who determined that 
phosphorylation of myosin was reliant on calcium concentration in all muscle types 
(Blumenthal & Stull, 1980). The importance of these findings serves as the cornerstone 
for most recent studies in the field of skeletal muscle potentiation, as it helps characterize 
and identify twitch potentiation. 
2.2.3 Evidence From Knock-Out (skMLCK-/-) Models 
 
Results from skMLCK knock-out models have helped confirm the suggested role 
and relationship of RLC phosphorylation mediated force potentiation. For example, Zhi 
et al. (2005) showed that brief tetanic stimulation of wildtype muscle increased RLC 
phosphorylation by ~ four fold and twitch force by 1.8 fold. However, when the same 
conditioning stimulus was applied to knock out muscle (skMLCK-/-) neither RLC 
phosphorylation or twitch force was elevated. This crucial research by Zhi et al. (2005) 
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confirmed that RLC phosphorylation by Ca2+/calmodulin dependent skMLCK is the 
primary mechanism of PTP in fast-twitch mouse muscle. Moreover, skMLCK over-
expression showed to enhance the rate of RLC phosphorylation and staircase potentiation 
in mouse EDL (Ryder et al., 2007). Although these results of the skMLCK-/- models do 
give support to the role of skMLCK, however, they also showed that low frequency 
repetitive stimulation registered an attenuated stair case potentiation of roughly 50% 
when compared to the wild type muscle. These data suggest that although skMLCK-
catalyzed phosphorylation of RLC is the primary mechanism for PTP, an additional 
mechanism may contribute to staircase potentiation (Zhi et al., 2005; Gittings et al., 
2011).  
2.2.4 Contraction Type Dependence 
 
 One of the most vital mechanical factors that modulates the ability of RLC 
phosphorylation to potentiate muscle is that of contraction type (Vandenboom et al., 
2013). The relationship between RLC phosphorylation and the potentiation of skeletal 
muscle has been characterized, in large part using isometric contractions. However, to 
date it has been seen that both rat and mouse skeletal muscle can be potentiated by the 
same conditioning stimulus for both isometric as well as concentric (dynamic force, 
work, and power) functions: 1 s at 160 Hz (Abbate et al., 2000), 3 of 500 ms at 100 Hz in 
10 seconds (Caterini et al., 2011). The analysis of PTP under dynamic conditions gives a 
more realistic mechanical model for assessing locomotor muscle function than does 
isometric contractions (James et al., 1996; Stevens and Syme, 1993a). While it had been 
suggested that an increased effect of Ca2+ on cross-bridge formation was a mechanism of 
PTP (Palmer & Moore, 1989), it has since been hypothesized that PTP is induced by 
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RLC phosphorylation, which is thought to increase the number of cross-bridges in the 
force generating state (Sweeney & Stull, 1990). To this end, a case can be made for the 
shortening speed dependence of concentric PTP (Abbate et al., 2000; Gittings et al., 
2012; Caterini et al., 2011) where at high shortening velocities, it is not possible for 
cross-bridges to remain in a force-generating state for a long time. Thus, it is at high 
velocities the effects of PTP on force generation are much more pronounced as the cross-
bridge distribution generally favors a non-force generating state which accounts for the 
noticeable effect of PTP, where as at slower speeds, phosphorylation mediated alterations 
to myosin structure favor a force-generating state (Caterini et al., 2011) therefore exerting 
less of an effect on force.  
2.2.5 β-Agonists and Force Potentiation 
 
The effects of β-adrenergic stimulation on muscle potentiation first appeared in 
the literature over 100 years ago. Since then, studies often examined the use of, but 
weren’t limited to, adrenaline and potassium chloride (Brown et al. 1949; Brown & 
Euler, 1938) and generally focused on twitch tension. Most recently, work on isolated 
mouse fast twitch skeletal muscle shows that β-adrenergic stimulation extends the 
potentiated state, demonstrating a possible function during the fight or flight response in 
mammals (Decostre et al., 2000). Furthermore, Grange et al. (1995) determined that even 
small force potentiation of the twitch can yield a significant increase in muscle force, 
work and power in the living animal. In this instance, the twitch is a fundamental 
mechanical output of an activated motor unit, where adrenergic stimulation will maintain 
this improvement for a longer time, thus allowing an animal to better cope with stressful 
situations.  
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Examination of the effects of adrenaline in the fatigued state date back to about 
the 1950’s, slowly giving rise to research involving PTP and the use of adrenaline, among 
other sympathetic amines. Contrary to literature at the time, evidence showed that a 
fatigued state of muscle was not necessary for demonstrating the potentiation effect of 
adrenaline (Goffart & Brown 1947). By 1948 it had been hypothesized that the main site 
of action of adrenaline on fatigued muscle was the fiber it’s self, and that adrenaline 
could augment twitch tension under circumstances in which no failure of transmission 
could be shown (Brown, Bulbring, & Burns, 1948). Research also gave evidence to the 
effects of ionic balance in the fluid surrounding the muscle (Goffart & Brown, 1947; 
Goffart, 1949) and the muscle itself (Goffart, 1947). Adrenaline had been seen to increase 
demarcation potential (Brown, Goffart, & Vianna Dias, 1950) as well as decrease K+ loss 
from muscles (Goffart & Perry, 1951). These results lead to conclusions that adrenaline 
prolonged the active state (Hill, 1949 b) of skeletal muscle, accounting for the observed 
increase in tension of twitches.  
Direct observation of the effects of β-adrenoceptor activation on contraction in 
both isolated fast and slow twitch skeletal muscle was being examined by the 1990’s 
(Cairns & Dulhunty, 1993). In rat soleus, β2-adrenoceptor agonists were used and 
induced an average of 15% potentiation of peak twitch and peak tetanic force. 
Interestingly, adrenaline had shown the ability to increase peak tetanic force by ~7% in 
both normal and denervated soleus fibers (Cairns & Dulhunty, 1993). This research 
displayed a contradictory result of potentiation in slow rodent fibers using terbutatline 
and adrenaline; this was attributed to greater β2-adrenoceptor density in the slow twitch 
muscles, as well as greater enhancement of adenylate cyclase activity. The most recent 
  
15 
work regarding β2-adrenoceptor agonists and post-tetanic potentiation has been 
conducted by Decostre et al. (2000) whose work will serve as a backbone for this section 
of the review. This paper identifies the effects of adrenaline on the PTP effect in the EDL 
of C57BL mouse skeletal muscle at (20C).  
2.2.6 β-Agonists and Mechanical Characteristics 
Adrenaline has been cited in literature for having a very small (Cairns & 
Dulhunty, 1993), or absent (Manning and Stull, 1982) effect on the isometric force of 
pre-tetanic twitches, although it has also been reported to increase by 15% (Goffart & 
Ritchie, 1952). More recently, this characteristic was supported in mouse EDL by both 
Decostre et al. (2000), as well as Andersson (2012) who observed increased isometric 
twitch force with 1 uM isoproterenol incubations. Decostre et al. (2000) found that 
adrenaline had small positive (+4%) effect on isometric force of pre-tetanic twitches. The 
intracellular effect of adrenaline has been mimicked using 8-bromo-cAMP and analogous 
compound, to help characterize whether adrenaline has specific action, or if these effects 
can be characterized across other β-adrenergic stimulants. The use of 8-bromo-cAMP in 
mouse EDL showed significant (+7%) increases in twitch force (Decostre et al., 2000).   
2.2.7 Temporal Twitch Parameters  
 The effects of adrenaline stem beyond altering twitch force in fast muscle. 
Evidence as far back as the 1950s shows adrenaline has an impact on the temporal 
parameters or kinetics of an isomeric twitch (Brown et al., 1948; Bowman & Ziamis, 
1958; Goffart & Ritchie, 1952) with relation to time to peak force (TPT; time required to 
reach max active force in ms), rate of force development (instantaneous rate of force 
development in mN/ms), and half relaxation time (time required for force to diminish 
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50% in ms). Decostre et al., (2000) saw that adrenaline slightly increased the time to peak 
force (20, and 300 s after tetanus), however this effect was small, a finding that 
corroborates some of the earliest findings (Goffart & Ritchie, 1952) suggesting 
adrenaline increased TPT more as time elapsed. Furthermore, adrenaline increased the 
rate of force development (CON 7.8 ms ± 0.9; EPI 8.8 ms ± 1.1) as well as the half 
relaxation time (CON 24.4 ± 1.2; EPI 29.9 ± 2.2). Thus, adrenaline may be responsible 
for an increased average twitch force as well as altered twitch kinetics, especially in 
combination with the enhancement of dF/dt that is a general characteristic of potentiated 
rodent muscle (Grange et al. 1995). 
2.2.8 Proposed Mechanisms of Epinephrine 
In 1979, myosin light chain phosphorylation and phosphorylase A activity in rat 
EDL was observed by Manning and Stull. Results showed prolonged tetanic stimulation 
lead to increased phosphorylation of LC2 (0.92 mol P/mol LC2) – helping confirm the 
role of LC2 phosphorylation in a twitch. Furthermore, phosphorylase A activity was low 
at rest, but after tetanic stimulation, activity of the enzyme increased in a time-dependent 
manner which attained maximum values after 2-3 seconds of relaxation. After achieving 
maximum activity, the phosphorylase activity diminished rapidly. Interestingly, post-
tetanic potentiation followed the same pattern that LC2 phosphorylation did, with a rapid 
rising phase followed by a slower descending phase. These researchers determined that 
these activities also required calcium concentrations greater than those at rest, implicating 
not only the role of myosin phosphorylation but transient calcium levels. Several years 
later, Manning and Stull (1982) examined the specific dephosphorylation of LC2 and the 
role of skMLCP. It was noted that slow rates of kinase inactivation coupled with low 
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activity of phosphatase could account for the persistence of LC2 phosphorylation well 
after tetanic stimulation, giving support to the possibility for prolongation of potentiation.  
The maintenance of LC2 phosphorylation in the presence of adrenaline is not yet 
fully understood, and thus its mechanisms are yet to be completely defined. On its own, 
adrenaline does not seem to activate the skMLCK at rest as LC2 phosphorylation does 
not increase in its presence (Manning & Stull, 1982; Decostre et al., 2000). Furthermore, 
the addition of adrenaline does not significantly increase phosphorylation level after a 
conditioning tetanus nor does the phosphorylation of skMLCK have any effect on 
skeletal muscle skMLCK (Edelman & Krebs, 1982). This cAMP-dependent protein 
kinase is also known to partially inhibit smooth muscle MLCK (Adelstein et al., 1978; 
Conti & Adelstein, 1981). The fact that adrenergic stimulation does not increase 
phosphorylation of RLC per se, but still maintains the high level following stimulation 
suggests an inhibition of the skMLCP (see Figure 4). The skMLCP (or PP1-M) is a class 
1-protein phosphatase, responsible for the dephosphorylation of LC2, countering the 
action of skMLCK. The most recent evidence suggests that PP1-M shares a common 
catalytic subunit with glycogen-bound protein phosphatase (PP1-G), another class 1 PP 
(Cohen, 1989; Gailly et al., 1996; Johnson et al., 1996; Egloff et al., 1997; Moorhead et 
al., 1998). In this case, it is well known that adrenergic stimulation leads to 
phosphorylation of the PP1-G, causing it’s catalytic sub-unit to dissociate (Hubbard and 
Cohen, 1989; Dent et al., 1990; Walker et al., 2000) and is subsequently inhibited by the 
phosphorylated form of inhibitor-1 (I-1, an endogenous PP inhibitor). I-1 is known to 
bind to the catalytic sub-unit of the type 1 phosphatases, although when 
unphosphorylated, I-1 is inactive and does not bind (Cohen, 1989; Bollen & Stalmans, 
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1992). The phosphorylation of the I-1 is catalyzed by a cAMP – activated protein kinase 
(Huang & Glinsmann, 1976) and in skeletal muscle, studies show that an increase of the 
phosphorylated (active) form of I-1 was present as a result of adrenergic stimulation 
(Foulkes & Cohen, 1979; Khatra et al., 1980). Thus, the current proposition by Decostre 
et al. (2000) is that PP1-M may follow the same mechanism of inhibition as PP-1G when 
subject to adrenergic stimulation, such that phosphorylation of the regulatory sub-unit, 
detachment and inhibition of the catalytic sub-unit happens via the binding of activated 
inhibitor-1.  
 
 
Figure 6. Potential mechanism of adrenaline during post-tetanic activation; inhibition of 
skMLCK. Modified from Stull et al., (2011). 
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2.3.0 Sympathetic Nervous System & Adrenoceptors 
The purpose of this literature review is to identify the role of β-adrenergic 
stimulation on mammalian skeletal muscle with special focus on β-agonist stimulation 
and post-tetanic muscle potentiation in mouse muscle. However, data from cats, rabbits, 
and human will be included. To do this, relevant literature regarding the structure, 
biochemistry, function, location, signaling mechanics, and history of β-adrenoceptors will 
be presented. These opening sections will not act as a complete and comprehensive 
review of each given topic, but merely fill in the gaps necessary to understanding the β-
adrenergic action on skeletal muscle. The review is comprised of five sections, including: 
a description of the sympathetic nervous system and adrenoceptor subgroups, identifying 
the role of β-adrenergic agonists, signaling mechanics of β-adrenoceptors within skeletal 
muscle, effects of 2-agonists in skeletal muscle, and the relationship between 
sympathomimetics and post-tetanic twitch potentiation in rodent muscle models. Section 
2.0 describes the sympathetic nervous system and adrenoceptors, including their sub 
groups. This section takes an overarching approach to elucidating the key components to 
sympathetic response, including: G-proteins and G-protein coupling receptors (GPCRs), 
β-adrenoceptor structure and sub-types, as well as α-adrenoceptor structure and sub-type. 
This section will approach each segment with consideration of location, biochemical 
properties, structure, function, and role within the system. 
 Among many functions, the role of the sympathetic nervous system (SNS) is 
defined by catecholamines, which elicit the responses governed by individual 
adrenoceptor within the system. In this case, the major signaling compounds under 
examination are adrenaline (epinephrine) or noradrenaline (norepinephrine)- each of 
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which can cause their own specific action on a given receptor. It is this ability that 
enables adrenoceptors to be targeted not only by physiologically present catecholamines 
such as adrenaline, but also as the target of synthetically altered agents as well. For 
example, in the case of therapeutic drug treatment, this synthetic tailoring is usually 
reserved for treatment of cardiovascular disease. β-adrenoceptors have been the main 
focus, specifically β2-adrenoceptors in the clinical setting.  
 As previously stated, the SNS relies on two major signaling compounds: 
epinephrine and norepinephrine. Epinephrine is a product of the adrenal gland, while 
norepinephrine stems from nerve axons following stimulation from acetylcholine (Lynch 
& Ryall, 2008). The binding of either of these compounds will prompt a physiological 
response depending on the receptor subtype targeted. Since 1948, these receptors have 
been referred to as adrenoceptors (Ahlquist, 1948). Within the classification of 
adrenoceptors, there are two major subgroups that have been the focus of academic 
attention. These two subgroups are known as the beta (β-adrenoceptor) and the alpha (-
adrenoceptor). In 1948, Raymond Ahlquist published a paper about the effects of six 
different sympathetic stimulators, primarily on cardiac muscle. In this study he designed 
two groups: the alpha (excitatory responses) and the beta (inhibitory responses). 
Although, today we know that these concepts are considerably more complex than 
proposed by Ahlquist, this delineation between the two types of adrenoceptor sub-types 
still exists. In fact, presently we can see nine different adrenoceptors: six alpha, and three 
beta. In the case of skeletal muscle, it is important to note that β-adrenoceptors dominate. 
Furthermore, over the last 20 years, β-adrenoceptor stimulation has shown to be useful in 
growth promotion in skeletal muscle (Agbenyega & Wareham, 1990; Carter et al., 1991).  
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2.3.1 G-Protein Coupled Receptor Family (GPCRs) 
The guanine nucleotide G-protein-coupled receptor family is the largest group of 
cell surface receptors in mammals, comprising greater than 1% of the human genome 
(Fredriksson et al., 2003). All adrenoceptors then, can be classified as belonging to the 
GPCR family. Of the GPCRs, the rhodopsin receptor is the most well known and 
characterized, this includes: dopaminergic, adenosine, histamine, - and β-adrenoceptors 
(Fredriksson et al., 2003). All GPCR receptors, such as rhodopsin, couple with 
heterotrimeric guanine nucleotide-binding regulatory proteins (G Proteins). Under 
physiological conditions, adrenaline and noradrenaline take effect by acting on a group of 
9 GPCRs- the adrenoceptors (Bylund et al., 1994; Davis et al., 2008). Adrenoceptors are 
broken into subtypes, which are coded by specific genes, all of which have selective 
agonists and antagonists for each receptor type (Alexander et al., 2007). When activated, 
all sub-types of the β-adrenoceptor can cause increases in intracellular levels of cAMP– 
however it is confirmed that this isn’t the only signaling pathway (Lefkowitz et al., 2002; 
Galandrin & Bouvier, 2006). A list of adrenoceptor subtypes and their respective G 
proteins and effectors can be found in this section of the review (see Table 1). G-Proteins 
are found in the cytoplasm, and conduct intracellularly to interact with an intracellular 
loop of the GPCR. In its active state, the G subunits bind tightly to the intracellular 
plasma membrane, where as Ga is in the inactive state, and remains attached to the G 
subunit.    
 When binding occurs with a ligand to the GPCR, the result is a conformational 
change leading to guanine diphosphate (GDP) being displaced from the Ga subunit by 
guanine triphosphate (GTP), in turn activating the Ga subunit and exposing the effector 
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site on the G dimer (Bockaert & Pin, 1999; Gilman, 1995). The Ga subunit alone can 
be divided into four major families: G as, Gai/o , Gaq/11 , and Ga12, which regulate activity 
of different second messenger systems. These delineations are based on primary 
sequence. With regards to β-adrenoceptors, current literature shows a strong coupling 
with Gas and Gai to initiate effectors for downstream pathways, of these include: adenylyl 
cyclase (AC), protein kinase A (PKA) and phospholipases (Dascal, 2001; Wenzel & 
Seifert, 2000).  
2.3.2 The β-Adrenoceptor 
 Under physiological conditions, epinephrine found in the blood is as a response to 
stress, fright or exercise, and undeniably affects performance. Desired effects stem from 
drugs, which act directly, or indirectly on β-adrenoceptor in both the brain and peripheral 
tissue (such as skeletal muscle). Since the mid 1980’s, three subtypes of on β-
adrenoceptors have been identified: β1-, β2-, β3- (Dixon et al., 1986; Emorine et al., 1989) 
and has been recognized as the most dominant adrenoceptor found in skeletal muscle, 
belonging to the GPCR family (Jossard, Durieux, & Freyssenet, 2013). In fact, the soleus 
of the rat contains 80-85% β2-adrenoceptors and 15-20% β1, while the plantaris of the rat 
is almost completely β2 (Kim et al., 1991). Experiments conducted on mice lacking β1-, 
β2-, or both, have shown that β2-adrenoceptors are responsible for the hypertrophy and 
anti-atrophy effects in muscle (Hinkle et al., 2002). With regards to specific subtype, the 
β2–subtype is most prevalent, with only roughly 7–10% of β1 present (Kim et al., 1991; 
Williams et al., 1984). Furthermore, when comparing β-adrenoceptor density and fiber 
type composition, it has been observed that slow twitch muscles have a greater density 
than their fast twitch counter parts (Martin et al., 1989; Ryall et al., 2002; Ryall et al., 
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2004). In some cases, this has been shown by radioligand binding assay (Kim et al., 
1991; Ryall et al., 2002, 2006; Williams et al., 1984). However, the work of McCormick 
et al. (2010) has challenged this using western blotting. Although it is unclear what this 
difference means with regard to function, the β-agonist response seems to be higher in 
fast muscle than slow (Ryall et al., 2002; Ryall et al., 2006; Kline et al., 2007). 
Interestingly, these results may seem counterintuitive considering that greater β-
adrenoceptor density would seemingly lead to greater response to stimulation, but it is 
hypothesized that this difference could come from rapid dampening of receptor function 
by phosphorylation in slow muscle (McCormick et al., 2010). 
 On the other hand, β2-adrenoceptor subtypes have wider distribution than the β1, 
and control a large portion of functions in the body, as well as mediate inotropic and 
chronotropic effect in the heart (Brodde, 2008). With regard to skeletal muscle, β2-
adrenoceptor stimulation has observed effects including increased growth, contraction 
force, and speed, as well as glycogenolysis (Bowman & Anden, 1981).  
 The signaling transduction pathway of β-adrenoceptors will be covered fully in 
the following sections of the review, although at this point it is important to touch briefly 
on signal transduction in general. Classically, it is believed that the majority of β-
adrenoceptor signaling happens through Gs coupling, which activates adenylate cyclase 
and thus, increases intracellular levels of cAMP (Rang et al., 2003; Alexander et al., 
2007). This classical assumption has recently been developed into a new outlook on β-
adrenoceptor signaling, with many layers of complexity where each receptor/G-protein 
couple show a wide variety of signaling mechanisms (Lefkowitz et al., 2002). Two 
factors that are important determinants of the pathway, which will be utilized are: 1) 
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protein-binding motifs of adrenoceptors, and 2) the agonist used to stimulated the 
adrenoceptor. When comparing β1-adrenoceptors and β2-adrenoceptors we see that the β1 
subtype couples with Gs and does not internalize well, however, the β2 subtype shows a 
much greater capacity for internalization. Furthermore, β2 subtypes can couple with both 
the Gs and the Gi for signal transduction, a term newly referred to in skeletal muscle as 
‘dual coupling’ (Gosmanov, Wong, & Thomason, 2002; Xiao, 2001). 
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Table 1. Adrenoceptor subtypes and G proteins; AKAP, A kinase anchoring protein; AC, 
adenylyl cyclase; PKA, protein kinase A. Modified from (Jossard, Durieux, & Freyssenet, 
2013). 
Adrenoceptor Subtypes and Respective G Proteins and Effectors 
 
Adrenoceptor  Beta 
Isoform β1 β2 
Predominant Gα isoform 
coupled 
Gαs Gαs 
 
Gαi family 
(αi1,i2,i3) 
Effector Activation of AC 
 cAMP 
Activation of PKA 
Activation of L-type Ca2+ 
channels 
Gαs mediated 
activation of AC 
 cAMP 
Activation of PKA 
Activation of L-type Ca2+ 
channels 
 
Gαi mediated 
Inhibition of AC 
 cAMP 
Inhibition of PKA 
 
 
Common secondary 
interacting  
proteins 
β-Arrestins 
AKAPs  
 
β1/β2-AR 
β1/α2-AR 
 
β-Arrestins 
AKAPs 
 
β2/α1D-AR 
β2/β1-AR 
 
 
Primary location  Heart 
Skeletal muscle 
Heart 
Lungs 
Vessels 
Kidney 
Skeletal muscle 
 
Major effect on skeletal 
muscle 
N/A Hypertrophy 
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2.4.0 The β-adrenoceptor Agonist 
 
 β-adrenoceptor agonists such as adrenaline are responsible for the stimulatory 
action of β-adrenoceptors. Common agonists include: salbutamol, bamuterol, terbutaline, 
fenoterol, mapenterol, formeterol, tulobuterol, carbuterol, bromobuterol, crimbuterol, 
salmeterol, and clenbuterol [1-(4-amino-3,5-dichlorophenyl)-2-ter-bu-tylaminoethanol]. 
Clenbuterol is a sympathomimetic amine, which mimics adrenalines action on receptors. 
Furthermore, like most agonists, clenbuterol is used for asthma and related bronchospasm 
(Maltin et al., 1993). Although used therapeutically for asthma, there is a clear ability to 
increase muscle mass and decrease body fat (Emery et al., 1984), known as the 
repartitioning effects. Due to these repartitioning effects, β-agonist administration has 
been examined in both animal and human models – hoping to fight muscle wasting 
(Carter el al., 1991; Kissel et al., 1998; Lynch et al., 2001; Maltin et al., 1993). 
Furthermore, those in bodybuilding, as well as strength and power sports for these same 
reasons have quickly adopted the use of β-agonists. (Lynch, 2002; Prather et al., 1995). 
Adrenaline accounts for 5-10% of the total catecholamines in the central nervous system, 
although its function is not fully understood, it is thought to control blood pressure and 
respiration. 
 As previously mentioned, while there are a multitude of β-agonists to describe, 
the main focus of this paper is on epinephrine. This is, in part, due to its substantial 
physiological significance- considering it’s role in mammalian responses like the flight-
or-flight response. Furthermore, epinephrine’s extensively researched background as a 
therapeutic aid renders it a prime candidate for further discussion on its benefits for 
skeletal muscle tissue. Considering the dominance of β2 receptors in skeletal muscle, a 
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primary focus will be β2 receptor agonists, such as adrenaline. Epinephrine belongs to a 
group of compounds known as catecholamines, which have an integral role in regulation 
and modulation of physiological responses in living organisms (Gulcin, 2009). 
Epinephrine acts as a neurotransmitter as well as a hormone. Release of the 
neurotransmitter is usually in response to stresses as an attempt to regulate physiological 
functions such as blood pressure, respiratory rate, vasoconstriction, cardiac stimulation, 
relaxation of smooth muscle, as well as several metabolic processes (Gulcin, 2009; 
Hoffman, 1996). Within the adrenal medulla, it is in the chromaffin cells and adrenaline-
containing cells that adrenaline is located (Gulcin, 2009; Verhofstad et al., 1985). 
Adrenaline is responsible for influencing the constriction of blood vessels, controlling 
tissue metabolism, as well as raising the blood glucose levels (Gulcin, 2009; Vollmer et 
al., 1997) and lactic acid levels (Gulcin, 2009; Cui et al., 2001). Although a crucial 
regulator of metabolic processes, adrenaline may be most well known for its role in acute 
stress reaction. This catecholamine is important in the physiological response to 
conditions that pose a threat to the physical integrity of the body– commonly known as 
the fight-or-flight response system.  Physiological concentration of epinephrine have been 
determined to be anywhere from 0.1–10nM in rats (Peters et al., 1998). Furthermore, a 
review of literature reveals that resting epinephrine varies from 4–140 nM in mice, 
however, more recent research using retro orbital bleeding observes a much smaller basal 
concentration of 1.1 nM (Grouzmann et al., 2003) thus showing great variability in this 
value, dependent on methods. In addition to findings by Grouzmann et al. (2003), the 
stress of a decapitation method elicited blood plasma levels of epinephrine to jump to 
27.3 nM, showing a methodological dependence of results. Regardless, the effects of β2 
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agonists on skeletal fibers are well documented. Responses range from showing 
decreased proportion of slow fibers and increased number of fast fibers in rat soleus 
muscle (Bricout et al., 2004; Dodd et al., 1996; Oishi et al., 2002; Ryall et al., 2002; Soic-
Vranic et al., 2005; Zeman et al., 1988) to increasing mass and isometric force production 
by roughly 15-20% (Beitzel et al., 2004; Harcourt et al., 2007; Lynch et al., 1999).   
2.5.0 β-adrenoceptor signaling in skeletal muscle 
2.5.1 β2-Adrenoceptor Signaling of cAMP 
The signaling of AC and cAMP by Gas is the most well defined signaling pathway 
of β2-adrenoceptors (Hinkle et al., 2002; Navegantes et al., 2000). The second messenger 
function of cAMP in skeletal muscle is both spatially and temporally regulated in muscle 
by numerous mechanisms (Tasken & Aandahl, 2004). These two mechanisms are 1) AC 
and 2) phosphodiesterases. It is well founded that AC is responsible for the conversion of 
ATP to cAMP, a process that plays host to a number of downstream affects in skeletal 
muscle. Thus, AC plays a major role in β2 agonist mediated signaling. The activity of 
each AC isoform generally increases after binding with a stimulatory Ga protein or 
decreases after binding with an inhibitory Gi protein (Hanoune & Defer, 2001).  
 The second mechanism for regulation of the effects of cAMP is phosphodiesterase 
(PDE). With 50 different PDE proteins stemming from 21 genes, the PDE family is vast 
(Venter et al., 2001). In mammals, there is a very similar structural framework to PDEs 
(Essayan, 1999; Francis et al., 2001), important in ensuring that these enzymes (PDEs) 
are used in hydrolyzing and inactivating cyclic nucleotides into 5-AMP (Bloom, 2002; 
Sham et al., 1991; Tasken, 2004). Therefore, intracellular cAMP levels are a product of 
the equilibrium between cAMP production via AC converting ATP, and degradation of 
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cAMP via PDEs. In other words, PDE is phosphorylated by PKA, leading to the 
hydrolysis of cAMP (Dodge-Kafka & Kapiloff, 2006), thus PKA has a negative feedback 
mechanism, which limits the temporal expression of cAMP. In skeletal muscle, there are 
multiple isoforms of PDEs expressed, and the activity of one specific PDE can strongly 
impact processes regulated by cyclic nucleotides (Bloom, 2002; Hetman et al., 2000; 
Sham et al., 1991). Work by Bloom (2002) was the first report on the expression profile 
of skeletal muscle PDEs since their discovery. Bloom defines three isoforms of PDE 
responsible for hydrolyzing cAMP: PDE4, PDE7, and PDE8. Interestingly, using cAMP 
assays, this researcher determined that PDE4 is the biggest contributing isoform of the 
three, for the degradation of cAMP. With regard to regulation of PKA, the MAPK family 
is found to decrease PDE activity (Dodge-Kafka et al., 2005; Hoffmann et al., 1999). 
Adrenaline has affects on PKA, and as such, the phosphorylation of PDEs as well. 
 
Figure 7. Gαs -, Gαi -, and Gβγ signaling pathways in skeletal muscle, all activated by a β2-
agonist stimulation via the β2-adrenoceptor. 
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2.6.0 The effects of β-adrenoceptor on skeletal muscle function 
2.6.1 β2-Agonist on Skeletal Muscle Fiber Type, Force, and Force Development 
The effects that β2-agonists have on skeletal muscle are vast. Current literature 
defines a role of β2-receptors, which includes: positive outcomes on fiber type, size, and 
force, among other things. β2-agonist administration has shown decreases of slow fiber 
proportions and increases of fast fibers in skeletal muscle, specifically in the soleus of 
rats (Bricout et al., 2004; Dodd et al., 1996; Oishi et al., 2002; Ryall et al., 2002; Soic-
Vranic et al., 2005; Zeman et al., 1988). In addition to the effects resulting in fiber type 
changes, there is increases in muscle mass as well as increased max isometric force 
production of skeletal muscle by 15-20% (Beitzel et al., 2004; Harcourt et al., 2007; 
Lynch et al., 1999). In an acute setting, major differences exist between fiber types when 
comparing the affects of epinephrine on force production (fast , slow ), adrenoceptor 
density (fast , slow ). Work by Andersson (2012) supports these conclusions, as these 
researchers reported increased isometric twitch force of the mouse EDL, with 1 uM 
isoproterenol in vitro. On the other hand, a number of studies on chronic exposure to β2-
agonist in animals have showed that when used in high doses (greater than human 
tolerance), β-agonists can elicit significant increases in muscle mass by 10-25% over 10–
20 days (Agbenyega & Wareham, 1990; Baker et al., 1984; Bardsley et al., 1992; 
Beermann et al., 1987; Carter et al., 1991). This capability of increased force vanishes 
several weeks after stopping treatment (Ryall et al., 2007), although, normalized force of 
muscle remains unchanged – this suggests that the increased ability to produce force is 
likely an effect of muscle mass (Beitzel et al., 2004; Harcourt et al., 2007; Lynch et al., 
1999). Furthermore, collagen deposits have been detected with treatment in skeletal 
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muscle, which may alter contractile properties of the muscle (Kumar and Sharma, 2006; 
Patiyal and Katoch, 2006). Literature also suggests a decrease in capillary density 
(Suzuki et al., 1997) and skeletal muscle blood flow (Beitzel et al., 2004; Rothwell et al., 
1987). Together, these changes could increase the distance for oxygen to diffuse, reduce 
oxygen supply to skeletal muscle, and increase muscle fatigability during extended 
contractile activity. So it would seem that there is equilibrium to be found between 
increasing max isometric force of the muscle, and the adverse effects on exercise 
capacity, which may limit the usefulness of β2-agonist on skeletal muscle. 
The first examples of epinephrine directly influencing skeletal muscle 
contractions came from Oliver and Schaefer (1895) who used extracts of the adrenal 
medulla to increase muscular contractions. This work has been supported dating back to 
before the 1900’s, and since then adrenaline has been known for it’s ability to increase 
max twitch tension in unfatigued muscle (Oliver & Schaefer, 1895; Gruber, 1922a, b; 
Goffart & Brown, 1947; West & Zaimis, 1949; Brown, Goffart & Dias, 1950; Goffart & 
Ritchie, 1952; Huidobro, Cubillos & Eyzaguirre, 1952; Goffart, 1952, 1954; Montagu, 
1955). By the 1950’s it had already been concluded that epinephrine and norepinephrine 
increased postural tone, improved respiration and increased contraction of other muscles. 
Furthermore, it was demonstrated that this increase in max tension was not in fact 
characteristic of all skeletal muscles. Although earlier work by Goffart and Ritchie (1952) 
concluded epinephrine depressed max tetanic tension, these results were considered 
flawed due to their methods resulting in vasoconstriction. Bownman and Ziamis (1958) 
showed that cat soleus muscle responded in the opposite fashion. Using three different 
amines (epinephrine, norepinephrine, and isoprenaline) these researchers showed that cat 
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tibialis anterior muscle consistently increased in sub-max and max twitch tension, while 
the soleus decreased in all cases. Along with increases in max twitch tension, these 
amines showed altered twitch time courses, where rate of development of tension 
decreased, while time to peak tension increased in the tibialis anterior, boosting the 
overall twitch duration by 17% (Bowman and Ziamis, 1958). This increase in time to 
peak had been observed earlier (Goffart & Ritche, 1951), who suggested that because in 
some cases time to peak increased, but not tension – these two factors or not closely 
interdependent. This lead to the idea that in skeletal muscle, adrenalines effects during the 
rising phase didn’t act through increased recruitment, because time to peak tension 
slowed as opposed to sped up.  
In the soleus muscle, similar characteristics were affected, where max twitch 
tension was diminished by 18% and overall duration of the twitch reduced by 33%. 
Interestingly, relaxation time of soleus muscle increased. One of the most profound 
results of this study was the delineation between muscle type and sensitivity to 
sympathetic amines, which had been noted by Goffart and Ritchie (1952), who believed 
that amine effect was relative to proportion of red to white fibers. The soleus was found 
to be much more sensitive to epinephrine and isoprenaline compared to the tibialis 
anterior, and ~ 50 fold less sensitive to norepinephrine than epinephrine or isoprenaline 
(see Table 2). This difference in sensitivity was hypothesized to be the cause for feeling 
weakness in the limbs during states of emergency or fright by decreasing tension in 
postural muscles by circulating adrenaline. These experiments began to show early signs 
of differences in fiber type sensitivity to β2 agonist/antagonists, as well as confirm 
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adrenaline’s action on muscle contractility, and show changes in rate of development of 
tension as well as time to peak tension.  
Table 2. The required intravenous dose (μg/kg) for minimal effect of epinephrine, 
norepinephrine and isoprenaline in the tibialis anterior and soleus. (Bowman and 
Zaimis, 1958). 
 Minimal Effect Intravenous Dose (μg/kg) 
 
Muscle Epinephrine Norepinephrine Isoprenaline 
Tibialis anterior 3-10 5-15 2-8 
Soleus 0.06–05 5-20 0.06-0.4 
 
2.6.2 β2-Agonist Molecular Signaling for Increased Force and The Role of Ca2+: Proof 
From Genetic Knock-Out Mice 
 
 Currently, it is well established that skeletal muscle displays increased peak force 
upon adrenergic stimulation (Brown et al. 1948; Cairns & Dulhunty, 1993b). However, 
despite its recognized role of this response, its molecular mechanism is still not fully 
defined. Up to this point, this review establishes that β2-agonists stimulate Gs protein 
receptors, which in turn activates AC, causing cAMP generation to activate PKA 
(Rockman et al. 2002). Furthermore, it is well documented that fast muscle fibers evoke a 
strong inotropic response to β2-agonists, as a result of a potentiated increase in [Ca2+] 
(Cairns & Dulhunty 1993a). This missing link between PKA mediated phosphorylation, 
and changes in [Ca2+] were recently addressed by Andersson et al (2012). These 
researchers used genetically altered mice, whom express a mutated RyR1 (ryanodine 
receptor type 1, on the sarcoplasmic reticulum) which cannot be phosphorylated by PKA, 
to show that mammalian fast muscle β2-agonists dependent increases in [Ca2+] and force 
are reliant on phosphorylation of the RyR1. Thus, implementing the sarcoplasmic 
reticulum as the connection between β-receptor stimulation and altered force.  
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 To support their work, Andersson and colleagues (2012) observed changes in 
twitch force of the EDL in both wildtype mice, as well as the RyR1 mutated mouse. 
Results indicated that, before the addition of β-agonists, both strains were similar in force 
development and force generation. However, after the β-agonist (isoproterenol) was 
added, wildtype muscles had significantly increased twitch force (control 140 kPa; 
isoproterenol 159 kPa) as seen in Figure 2, while the mutated mice exhibited no change 
in force (control 145 kPa; isoproterenol 142 kPa). Furthermore, rate of force development 
increased in wildtype mice, while there was no change in the mutated mice. These results 
suggest the importance of RyR1 phosphorylation as a mechanism for β-agonist action on 
the SR, and that this phosphorylation is critical in promoting enhanced Ca2+ release 
during contraction. 
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Figure 8. A. Effect of isoproterenol on force generation in wildtype EDL; B. Effect of 
isoprterenol on peak force in wildtype EDL; C. Effect of isoproternol on force generation in 
RyR1 mutated EDL; D. Effect of isoproternol on peak force in RyR1 mutated EDL. (Anderson et 
al. 2012) 
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Statement of The Problem 
 
 
3.1.0   Central Research Question 
 
The primary objective of the proposed research was to test whether β-adrenergic 
stimulation augments the time-course and characteristics of concentric twitch 
potentiation, and if these changes could be correlated to altered myosin phosphorylation. 
To this end, we assessed concentric twitch potentiation as well as myosin 
phosphorylation in wildtype as well as skMLCK-/- knockout mice, in both the presence 
and the absence of epinephrine.  
3.2.0   Hypothesis 
 
We hypothesized that a prolongation of the potentiated state in response to 
epinephrine incubation would be observed in wildtype muscles. In contrast, we expected 
that no prolongation of PTP would be observed in skMLCK-/- knockout muscles. We 
expected this difference to be due to the fact that epinephrine prolongs myosin 
phosphorylation (Decostre et al. 2000), a mechanism that will affect wildtype but not 
skMLCK-/- knockout muscles. On the other hand, a contrary result would be grounds to 
reject the null hypothesis, confirming that epinephrine incubation alters concentric twitch 
potentiation via some other mechanism.  
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3.3.0   Assumptions 
 
We assumed that there are no phenotypical differences between the wildtype and 
skMLCK/- mouse, other than the skMLCK gene ablation and coat color (aguti coat). For 
example, the work of Gittings et al. (2011) genotyped both wildtype and skMLCK-/- EDL 
function and structure; showing there was no significant difference between fiber 
compositions of the EDL between genotypes (Figure 9), and that the ablation of the 
skMLCK gene has little effect on unloaded shortening velocity. In addition, we assumed 
that there is no presence of other intracellular kinases that are capable of phosphorylating 
the myosin RLC.  
 
Figure 9. MHC expression in mouse EDL muscle (Gittings et al., 2011); (A, B) Representative EDL 
cross- sections from wildtype (a) and skMLCK knockout (c) mice incubated with antibodies to identify 
type I (blue), type IIa (green), type IIb (red), and type IIx (unstained) fibers. (C, D) Representative EDL 
serial cross-sections of (a) and (b) from aildtype (b) and skMLCK knockout (d) mice stained with 
antibodies to identify type IIA (green) and type IIx (purple) fibers. Fibers with positive staining for two 
MHC isoforms were identified as Hybrid fibers. Bars represent 50 uM. 
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Methods 
4.1.0   Wild-Type (WT) & skMLCK Knockout (KO) Mice 
 
Two independent strains of C57BL/6 adult mice (2-5 months) were used through 
the experiment. The first strain, wildtype mice acquired were ordered from Charles River, 
Drummondville QC Canada, and housed at Brock for ~1 week before experiments began. 
The second strain, the skMLCK-/- mice (C57Bl/6 background) were obtained from our 
own breeding colony at Brock University. The non-dominant coat color allele is spatially 
associated with the targeted gene for myosin light chain kinase knockout, allowing 
convenient manipulation of coat phenotype as a marker for each genetic strain. As such, 
all wildtype (WT) mice were black (homozygous for the recessive non-agouti allele) and 
all skMLCK knockout (KO) mice were agouti (light brown). Mice were housed in small 
groups (1-5) and given free access to standard chow and water until required for 
experimental procedures. All experiments are approved by the Brock University Animal 
Care and Use Committee (AUP # 14-06-01). 
4.2.0   Experimental Apparatus 
 
All contractile experiments were completed using a custom-designed apparatus 
(from Aurora Scientific, Inc.) capable of accurately controlling muscle length and a 
variety of environmental factors. The mouse extensor digitorum longus (EDL) muscle 
was suspended in an oxygenated organ bath (Radnoti Glass Technology, Inc) containing 
a physiological salt solution maintained at constant temperature using an Isotemp 3013S 
circulator (Fisher Scientific). Muscle stimulation was applied using flanking platinum 
electrodes driven by a Model 701B biphase stimulator (Aurora Scientific, Inc.). Muscle 
length was monitored using a horizontal stereo zoom microscope (Bausch & Lomb), 
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which could be manually controlled at increments of 0.01mm using a sliding micrometer 
(Velmex, Inc). Contractile data was collected at 1000Hz using a 305B servomotor 
acquired through a 604C analog to digital interface, and controlled by a dual-mode lever 
system (ASI). Data acquisition and basic analysis was performed using ASI 600a 
software (Version 1.60) run on a LINUX based operating system, and further examined 
using Prism 6 Graphpad. 
 
Figure 10. ASI organ bath containing Tyrode’s solution for in vitro intact muscle experiment. 
 
 
 
 
Motor 
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4.3.0   Surgical Removal of EDL & Muscle Preparation 
 
 Surgical removal procedure has been standardized in the lab of Dr. Rene 
Vandenboom (Vandenboom et al., 2013; Gittings et al., 2014). Animals were initially 
sedated with an intraperitoneal injection of Somnitol (Soldium-Pentobarbitol, see 
Appendix A, Table A.1) diluted 1:10 with saline (0.025ml/g body weight). The EDL 
was carefully excised from each hind limb after a non-absorbable braided silk (4-0) 
suture is fastened to the proximal and distal tendons. One EDL was mounted into the 
experimental apparatus immediately while the other was maintained in an oxygenated 
Tyrode’s solution on ice (see Appendix A, Table A.2). Following EDL removal (See 
Appendix B), the animals were euthanized by lethal injection into the heart (0.05ml/g 
body weight) and disposed of according to Brock University Animal Facility protocol.  
The Tyrode solution proposed for use in all experiments served as a favorable 
environment for muscle contraction and was intended to provide muscle tissue with the 
essential substrates and ions present in vivo. Final ionic concentrations are (in mM): 121 
NaCl, 5 KCl, 24 NaHCO3, 0.4 NaH2P04, 0.5 MgCl, 1.8 CaCl, 5.5 D-Glucose, and 0.1 
EDTA. The solution was continuously gassed (95% O2, 5% CO2) using a scintillated 
glass dispersion valve (Radnoti) and maintained at 25 C (+/- 0.5  C).  
4.4.0   Experimental Design 
 
The isolated EDL in vitro model was used for all experiments to elucidate the role 
of epinephrine administration on post-tetanic twitch potentiation. Two identical sets of 
experiments were conducted on EDL muscles from wildtype and skMLCK-/- mice for 
analysis of: 1) contractile function, and 2) biochemical quantification of RLC 
phosphorylation. Each set of contractile experiments involved the quantification of post-
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tetanic potentiation and contractile performance, as well as phosphorylation of the 
myosin RLC. Contractile data was collected from a total of 8 muscles from each group 
(wildtype and skMLCK-/-) using matching experimental procedures.  An example of 
experimental design and protocol can be found in Figures 11 and 12, below. 
 
 
Figure 11. Experimental Group Design (CON, Control; EPI, Epinephrine) 
  
42 
The second set of experiments was conducted to observe the EDL in the 
potentiated state, under the influence of varying amounts of epinephrine, after which the 
EDL was rapidly removed from the in vitro environment (<15 seconds) and freeze 
clamped for biochemical analysis. The collective data proposed in this project therefore 
represents an analysis of twitch force modulation by post-tetanic potentiation during 
resting conditions and a more comprehensive account of contractile function and 
physiological/biochemical status under the influence of epinephrine.  
Figure 12. Experimental Protocol (CS, Conditioning stimulus) 
 
4.4.1  Epinephrine Preparation 
 
On the day of an experiment, fresh epinephrine [(±)-Epinephrine hydrochloride, 
E4642 SIGMA] was prepared into a 1mM stock solution. Next, each Tyrode bath was 
prepared separately depending on the epinephrine concentration for that experiment (1 
μM). Experimental concentrations of epinephrine were determined based on previous in 
vitro experiments (Decostre et al. 2000; Andersson 2012) as well as pilot experiments of 
epinephrine titrations to determine optimal concentration of 1 μM (that which caused 
maximum effect on PTP) seen in Figure 13. 
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Figure 13. Titration of three different epinephrine concentrations (1, 2, 3 uM) on concentric PTP 
time course of wildtype EDL 25°C 
 
4.4.2   Optimal Length  
 
To normalize all force data fiber diameter, resting muscle length and optimal 
muscle length (Lo) was measured during initial force-length measurements. Optimal 
length (Lo) is defined as the length at which peak active twitch force (Pt) was elicited and 
will be used as the reference length for all shortening amplitudes. Considerable attention 
was given to the control of muscle length, as twitch force potentiation is highly length-
dependent. 
4.4.3   EDL Stimulation 
 Two pre-programmed stimuli were used to excite the EDL preparations during all 
contractile experiments. All were applied at supramaximal voltage to ensure that all 
motor units were fully activated. For tetanic contractions, 150Hz stimulation represents a 
supramaximal motor-unit firing rate producing completely fused tetani. The conditioning 
stimulus (CS) for the potentiation protocol is standard for our lab, and was intended to 
maximize RLC phosphorylation and PTP, while simultaneously minimizing fatigue. 
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4.4.4   Stimulation Profiles 
 
 S1. Single Muscle Twitch    1Hz 
 S2. Conditioning Stimulus (CS)    4, 100Hz, 400ms, 10s 
4.5.0   Calculation of Pre-Tetanic and Post-Tetanic Twitch Force  
 
Central to the calculation of relative measures such as force potentiation was the 
determination of a representative control contraction to serve as a reference. For each 
experiment, twitch force was measured prior to the conditioning stimulus as an average 
force of three twitches at 20 second intervals. After the conditioning stimulus, twitch 
force was measured several times as the value of post-tetanic twitch force. The ratio of 
post-tetanic to pre-tetanic twitch force (post / pre) at any given time represents a 
normalized value of potentiation.  
The PTP protocol was designed to produce long lasting PTP in wildtype muscles 
as well as a lesser potentiation in skMLCK-/- muscles. After applying the standard 
conditioning stimulus (100Hz, 400ms, 10s), concentric twitches were measured at 5, 10, 
15, 30, 60, 120, 180, 240, 300, 360, 420, and 480-seconds (following cessation of the 
CS). The concentric twitches were shortened from 1.05 to 0.95 Lo at a speed of 30% 
Vmax. Therefore, the time to shorten will be 77 milliseconds. 
4.6.0   Peak Force Production 
 
Peak force is defined as the highest or maximal tension produced in response to 
twitch (Pt), measured in mN. To obtain the peak active force for each individual twitch, 
we used the measured total force and subtract the passive force. The resulting traces are 
shown below in Figure 14. 
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Figure 14. Total, Passive, and Active Force Traces of a Concentric Twitch (EDL). Active force 
during shortening is calculated by subtracting passive force from total force. 
4.7.0   Rate of Force Development (dF/dt)  
 
  The peak values for rates of force development (mN/ms) were determined using 
the ASI 600a software package, which plots a rate function of instantaneous values of 
dF/dt following smoothing using a Savitsky-Golay Filter.  
4.8.0   Biochemical Analysis of Muscle Tissue 
4.8.1 Quantitative Determination of Proteins: Bradford Assay 
 
 Materials and methods for performing Bradford assay using BSA standard were 
provided by the lab of Dr. Sandra Peters (Bradford, 1976; from J. R. Choptiany). These 
experiments used a BSA standard and fresh (day of) whole muscle homogenate of 
wildtype EDL muscle prepared in lysis buffer. Muscle samples were removed from the -
80C freezer and immediately placed in liquid nitrogen. After removing the silk sutures 
from each end of the muscle, samples underwent buffer treatment with both acetone and 
water-based protein percipitation solutions (Appendix D) and homogenization in a glass 
homogenizer. Upon removing frozen muscles from the -80C freezer, protein content of 
each sample was determined using Gen5 2.09 analysis software by running homogenate 
samples against a dilution spectrum of BSA standard (1, 0.5, 0.25, 0.125, 0.05, 0) and 
measuring relative absorbance (BIO-TEK Synergy HT). A full list of materials, reagents, 
procedure, apparatus and results used during this protocol can be found in Appendix C. 
Total Force Passive Force Active Force 
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4.8.2 Gel Electrophoresis and Western Blotting 
 
 Materials and methods for performing gel electrophoresis and immunoblotting for 
myosin RLC phosphorylation were provided by the lab of Dr. James Stull (Zhi et al., 
2005; Ryder et al., 2007; Gittings et al., 2014). A detailed list of solutions and methods 
used in this process can be found in Appendix D. Myosin regulatory light chains are 
small (18-20 kDa) acidic (net charge of -18) proteins that migrate easily in 
polyacrylamide gels containing glycerol for density. RLCs are denatured with 
tricholoroacetic acid (TCA) and solubilized in urea to dissociate RLC from myosin heavy 
chain. The addition of single phosphate introduces two additional negative charges at pH 
8.6 (that of the running buffer) so the phosphorylated protein migrates faster than the 
non-phosphorylated RLC. The first day of procedures involves solution preparation, 
sample preparations, electrophoretic separation, transferring the protein to a nitrocellulose 
membrane, followed by blocking and overnight incubation with the primary antibody. 
The second day of procedures involves immunoblotting and imaging. Determination of 
percentage (%) phosphorylation is measurement of the band density for the mono-
phosphorylated band divided by the band density of the total protein (Equation 1). 
% Phosphorylation = (Density Mono-P band) / (Density Total protein) 
 
% Phosphorylation = (Density Mono-P band) / (Density Mono-P + Density Non-P) 
 
Equation 1. Calculation for determining the % phosphorylation of RLC protein bands. 
Mono-P, mono-phosphorylated RLC band; Non-P, non-phosphorylated RLC band. 
 
 Myosin RLC phosphorylation was measured in isolated mouse extensor digitorum 
longus muscles after being snap-frozen in in clamps pre-cooled in liquid nitrogen. 
Samples were then placed in an acetone-based protein precipitation solution (0.5 g TCA; 
7.71mg DTT; 5 mL Acetone) slurry and brought to room temperature. Following this, 
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silk sutures were removed and muscle samples were placed into a glass homogenizer 
containing water-based protein precipitation solution (0.5 g TCA; 7.71mg DTT; 5 mL 
dH2O). Once homogenized, resuspension takes place by washing protein pellets in ether 
and adding urea sample buffer. Prepped samples then underwent electrophoretic 
separation, where the nonphosphorylated RLC is separated from the mono-
phosphorylated RLC (Zhi et al., 2005; Ryder et al., 2007). Antibodies raised in rabbits to 
purified skeletal RLCs (proided by the lab of James Stull) were used for the appropriate 
analyses. Goat Anti-Rabbit IgG horseradish peroxidase (Santa Cruz Biotechnology) 
secondary antibodies were used with ECL prime luminol and oxidizing reagents (GE 
Healthcare), and quantitative measurements were processed on a Li-COR C-DiGit Blot 
Scanner and analyzed in Image Studio.  
 
Figure 15. Images of each step of the urea/glycerol-PAGE method used in this project. Top 
Middle, an example of whole EDL muscle homogenate during ether washing to remove residual 
TCA; Bottom Left, C-DiGit Blot Scanner used in the quantification of myosin RLC 
phosphorylation; Bottom Right, Electrophoresis and transfer tank (Bio-Rad Technologies) along 
with power supply. 
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4.9.0   Laboratory Procedures 
 
Prior to a standard 30-minute equilibration period, the EDL was stimulated 
(150Hz, 1000ms) to produce a contraction forceful enough to remove any compliance 
and possible slippage in the tendon-suture unions. Subsequently, a single twitch was 
applied at 0.05Hz while sequentially increasing current intensity until a maximum twitch 
force was reached. The stimulus intensity was then be increased ~25% and remained at 
this magnitude for the duration of each experiment to ensure maximal excitation of all 
motor units.  
The resting EDL was then manipulated to determine optimal length, Lo. Starting 
at ~0.7Lo the muscle will be lengthened at 0.02 Lo increments while receiving a twitch 
stimulus at each length. The muscle length at which active twitch force reached a 
maximum was documented as Lo and used as the reference length for all subsequent 
length steps. The accuracy of all length changes and positions was corroborated manually 
using a stereo zoom microscope (Bausch & Lomb) to provide measurements of actual 
muscle length (mm). 
Following these standard preliminary procedures, a contractile experiment was 
conducted. Each experiment was officially terminated when the EDL is rapidly freeze-
clamped and stored at -80 C for future analysis. Prior to the mounting of each fresh EDL 
muscle, the Tyrode solution was replaced with a fresh aliquot and given sufficient time to 
equilibrate. 
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4.10.0 Data Analysis & Statistics 
 
The primary investigation of this research was the effect of epinephrine on 
concentric twitch force potentiation in mouse EDL muscle. Data was initially screened 
for outliers, and checked for statistical assumptions of normal distribution and equality of 
variances. Following this screening, appropriate analysis was selected for each set of 
data. For each measure, significant difference between groups will be determined using 
(p < 0.05). All data will be presented as the sampled mean +/- SEM and was analyzed in 
Prism 6 Graphpad. 
To analyze within genotype factors such as absolute concentric twitch force, 
relative concentric twitch force (i.e., wildtype vs. wildtype) a two-way repeated measures 
ANOVA for each condition was used, followed by a Holm-Sidak’s correction. To 
analyze within genotype factors affected by epinephrine (i.e., wildtype control vs. 
wildtype epinephrine) a two-way repeated measures ANOVA was used, followed by a 
Sidak’s multiple comparisons test. 
To analyze between genotype factors such as absolute concentric twitch force, 
relative concentric twitch force (i.e., wildtype vs. skMLCK-/-) a two-way repeated 
measures ANOVA for each condition was used, followed by a Sidak’s correction. To 
analyze peak tetanic force values between genotypes, multiple t-tests were conducted 
using by Sidak’s correction (P < 0.05). 
To determine the effect of the CS on myosin phosphorylation in wildtype 
muscles, a two-way ANOVA was conducted, followed by a dunnet’s test for significance 
over time. Multiple t-tests were used for each time-point to determine the effect of 
epinephrine on myosin phosphorylation (wildtype control vs. wildtype epinephrine).  
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In order to fully characterize the results of this study, the contractile data before 
treatment with epinephrine (i.e., mean twitch force, peak twitch force, and tetanic force) 
and was analyzed in two ways; absolute force and relative, which will be denoted using 
subheadings. Within each measure of force, a between genotype (wildtype vs. skMLCK-/-
) as well as within genotype (effect of time) analysis was conducted. Following this, the 
epinephrine data was analyzed in the same fashion. After illustrating the effect of 
epinephrine treatment on contractile function, the twitch kinetics data was examined (rate 
of force development, rate of relaxation, time to peak tension) both with and without 
epinephrine treatment. Lastly, analysis of the biochemical data (myosin phosphorylation) 
collected in this study was conducted.  
Statistical test specifics i.e., main effect, F-score and statistical significance will 
be located in the text, while details regarding statistical testing, levels of significance and 
post-hoc analysis can be found in figure and table captions. Any data or statistical 
information not presented directly in the Results section can be found throughout the 
Appendix D, E, F, and G as referenced. 
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Results 
 
5.1.0 Mouse Characteristics 
 
 In these experiments, adult mice (3-5 months) from two different genotypes 
(wildtype and skMLCK-/-) were split into two experimental categories: contractile and 
biochemical. No significant difference was found for mass (g) between wildtype and 
skMLCK-/- mice used in the biochemical experiments; however the mean mass of 
wildtype mice in the contractile experiments was found to be significantly higher than 
mean skMLCK-/- mass (P < 0.05). The exact age of mice (days) in the wildtype genotype 
could not be determined as it was not presented from the breeder (Charles River), 
however this group is confirmed to be adult mice aged ~91-152 days. On the other hand, 
mice from the skMLCK-/- mice had a mean age of 97.5 days, a result that may account for 
the difference in weight between genotypes. For the present discussion, it is noted that 
animals in both genotypes have reached sexual maturity (Fox et al., 2006); thus 
differences in both age and mass probably did not significantly influence the structure or 
function of the EDL muscles enough to influence the main results. Means ± SEM for 
mice involved in either contractile or biochemical experiments are presented in Table 3. 
 
 
Table 3. Mean mass for mice used in both contractile and biochemical experiments. 
 
Genotype 
Mean Mouse Mass (grams) 
Contractile Experiments Biochemical Experiments 
     
             Wildtype 25.8 ± 0.6 g 28.3 ± 0.9 g 
skMLCK-/- 19.4 ± 0.1 g 22.3 ± 2.9 g 
Values are presented as mean ± SEM; mass in grams (g) for mice in contractile experiments (n = 5) and 
biochemical experiments (n = 6 - 12);* Value is significantly greater than skMLCK-/- genotype (Tukey’s 
HSD, P < 0.05). 
* 
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5.2.0 Contractile Measures 
5.2.1 Absolute Concentric Twitch Force 
 
 5.2.1.1 Within Genotype Analysis 
 
 Absolute mean concentric twitch force was enhanced in both genotypes above 
unpotentiated values following the conditioning stimulus.  Results of a two-way repeated 
measures ANOVA indicated that both genotypes displayed enhanced mean force over 
time (Table 4; Wildtype, P <0.0001; skMLCK-/-, P <0.0001). A second two-way 
repeated measures ANOVA was then conducted to analyze the effect of the conditioning 
stimulus and time on absolute peak concentric force. Results of the ANOVA indicated 
that absolute peak force followed a similar trend to mean force in both wildtype (P < 
0.0001) and skMLCK-/- muscles (P < 0.0001); displaying significantly elevated levels 
after the conditioning stimulus (Table 4). One difference, however, is that skMLCK-/- 
control muscles did not exhibit elevated peak twitch force by the 8-minute mark (P = 
0.907).  
5.2.1.2 Between Genotype Analysis 
 
A between genotype analysis showed wildtype muscles displayed a larger 
increase in absolute twitch force than skMLCK-/- muscles after the conditioning stimulus 
(Table 4; P < 0.0001); in contrast there was no significant difference between the 
unpotentiated mean twitch force (P  = 0.078). In addition to twitch force measurements, 
an analysis of peak tetanic force during the CS was conducted (Table 4). Indeed, Figure 
16 shows that peak tetanic forces (control condition) were not significantly different 
between genotypes. Full results of the post-hoc multiple comparison tests of mean force, 
peak force, and peak tetanic values are presented as means ± SEM in Table 4. 
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Figure 16. Representative trace of tetanic force (mN) in wildtype (A) and skMLCK-/- (B) control 
muscles during the conditioning stimulus (100Hz).  
 
5.2.2 Relative Concentric Twitch Force: PTP 
 
It was initially hypothesized that wildtype muscles would show greater concentric 
force potentiation (post-CS/pre-CS) than skMLCK-/- muscles over the 8-minute time 
course. To this end, a two-way repeated measures ANOVA was conducted for mean 
concentric force potentiation between wildtype and skMLCK-/- muscles which indicated 
that there was a main effect for genotype in the control condition (Table G.1; P < 0.01). 
Furthermore, a two-way ANOVA was conducted to determine the effect of time in 
combination with a condition stimulus on relative force production. This analysis 
established a significant main effect for time in both wildtype (P < 0.01) and skMLCK-/- 
(P < 0.0001); the results of which are presented as means ± SEM in Table 4. 
A new two-way repeated measures ANOVA was then conducted to determine the 
effect of the CS on relative peak concentric force. Results of the ANOVA revealed that 
peak concentric force potentiation showed similar trends to that of mean force; displaying 
significantly increased PTP after the CS (Table 4). Moreover, while skMLCK-/- muscles 
A 
B 
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(P < 0.0001) exhibited a slight decrease in PTP by the 8-minute mark, wildtype muscles 
(P < 0.0001) exhibited a maintenance of ~4.00  ±  0.02% PTP by 8-minutes; in contrast 
to mean force PTP, which returned completely to unpotentiated values. The full 8-minute 
time course of PTP for peak twitch force and mean twitch force are depicted in Figure 17 
and Figure 19, respectively.  
 
 
 
 
 
 
 
5.3.0 Effect of Epinephrine Treatment on Force Production and Post-tetanic 
Potentiation 
5.3.1 Absolute Concentric Twitch Force 
 5.3.1.1 Within Genotype Analysis 
 
Following control condition experimental protocol, EDL muscles from both 
genotypes underwent a 30-minute incubation periods in a 1 μM epinephrine-Tyrode’s 
solution. A two-way repeated measures ANOVA for mean concentric twitch force 
indicated a main effect for condition in both the wildtype (P < 0.0001) and skMLCK-/- 
muscles (P <0.0001). Follow up multiple comparisons tests reveled that epinephrine 
Figure 17. Relative peak concentric twitch potentiation (post-CS/pre-CS) of Wildtype (A) and skMLCK-
/- (B) control muscles during 8-minute experimental time course following high-frequency conditioning 
stimulus (n = 8).  
 
5 10 15 20 30 60 12
0
18
0
24
0
30
0
36
0
42
0
48
0
0.9
1.0
1.1
1.2
1.3
1.4
Time (seconds)R
e
la
ti
v
e
 T
w
ti
c
h
 F
o
rc
e
 (
P
o
s
t 
C
S
/ P
re
 C
S
)
5 10 15 20 30 60 12
0
18
0
24
0
30
0
36
0
42
0
48
0
0.9
1.0
1.1
1.2
1.3
1.4
Time (seconds)R
e
la
ti
v
e
 T
w
ti
c
h
 F
o
rc
e
 (
P
o
s
t 
C
S
/ P
re
 C
S
)
A B 
  
55 
treatments enhanced mean concentric twitch force by 11.8 ± 3.0% and 11.1 ± 2.4% [5 
seconds post-CS] compared to the wildtype and skMLCK-/- control values, respectively 
(Table 4: P < 0.0001). Moreover, epinephrine incubation was able to maintain elevated 
levels of concentric twitch force in wildtype (24. 3 ± 5.0%, P < 0.0001) and skMLCK-/- 
muscles (20.1 ± 5.3%, P < 0.0001) by the 8-minute mark. In addition, epinephrine 
incubation had no effect on the unpotentiated mean concentric twitch force of skMLCK-/- 
muscles (P = 0.99); however, wildtype muscles displayed a small change following 
treatment (Table 4; P < 0.05).  
As expected, epinephrine treatment also affected absolute peak twitch force of 
wildtype (P = 0.0002) and skMLCK-/- muscles (P = 0.0042). Values of peak twitch force 
showed nearly identical trends with response to epinephrine in contrast to mean force; 
exhibiting elevated values at all time points after the CS in wildtype and skMLCK-/- 
muscles (Table 4; P < 0.0001). Furthermore, epinephrine treatment was unable to elevate 
the unpotentiated peak twitch force of skMLCK-/- muscles (P = 0.45); while wildtype 
muscles displayed a 6.2% increase. In addition to twitch force measurements, an analysis 
of peak tetanic force during the CS was conducted to determine the impact of epinephrine 
treatment, as well as to ensure muscles would redevelop tetanic force after the 30-minute 
incubation period. Indeed, tetanic force was redeveloped, and no variation was detected 
between wildtype and skMLCK-/- muscles (Figure 18).  
 5.3.1.2 Between Genotype Analysis 
 
A second two-way ANOVA was conduced to compare the impact of epinephrine 
treatment and peak twitch forces between genotypes. Results of the two-way ANOVA 
revealed an interaction between genotype and epinephrine treatment (P = 0.0041); 
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indicating that epinephrine treated wildtype muscles exhibited greater peak concentric 
forces than skMLCK-/- muscles. Results of follow-up tests from each two-way ANOVA 
conducted for the affect of epinephrine on force are provided as means ± SEM in Table 
4. 
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Figure 18. Representative trace of tetanic force (mN) in wildtype (A) and skMLCK-/- (B) epinephrine 
treated muscles during the conditioning stimulus (100Hz).  
5.3.2 Relative Concentric Twitch Force: PTP 
 
5.3.2.1 Within Genotype Analysis 
 
 An analysis of post-CS concentric force responses following epinephrine 
incubation was conducted using a two-way repeated measures ANOVA. Results 
indicated a significant interaction between mean concentric PTP and treatment with 
epinephrine in wildtype (P < 0.0001) and skMLCK-/- muscles (P < 0.0001). A follow up 
multiple comparisons test exhibited that epinephrine incubation enhanced mean 
concentric PTP by 9.6 ± 2.6% and 10.2 ± 4.2% compared to the wildtype and skMLCK-/- 
control values, respectively (Table 4; P < 0.0001). Furthermore, at the 8-minute mark; 
epinephrine treated muscles from both wildtype and skMLCK-/- mice displayed a 19.3 ± 
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1.6% and 15.7 ± 10.2% increase to PTP compared with their control values, respectively 
(P < 0.001). Data plotted in Figure 19 shows how concentric PTP of both epinephrine 
treated and control muscles peaked immediately after the CS in wildtype and skMLCK-/- 
muscles; slowly dissipating over the course of the 8-minute time window studied. 
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Figure 19. Effect of epinephrine on concentric twitch force potentiation after a CS in Wildtype (A) and 
skMLCK-/- (B) mouse EDL at 25°C (n = 8). Relative twitch force, determined by normalizing experimental 
twitch force to unpotentiated twitch force (Post-CS / Pre-CS); Closed bars, Control; Open bars, 
Epinephrine Treated; *** indicates that value is significantly greater than unpotentiated control value 
(Within Genotype, Holm-Sidak’s correction, P < 0.0001); ☨ Indicates that value is above unpotentiated 
value as well as CON (Within Genotype, Sidak’s correction, P < 0.001) 
 
 
 
 
A 
B 
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Table 4.  The effect of 1 μM epinephrine incubation on force production and PTP in 
wildtype and skMLCK-/- mouse EDL (25°C) 
 
 
Time Point 
Potentiated 
Un-potentiated %Δ  5 Seconds %Δ 8 Minutes %Δ 
Mean Concentric Force (mN) 
Wildtype 10.0 ± 0.9 
4.0% 
13.0 ± 1.3 
12.3%‡ 
10.0 ± 0.9 
24.0%‡ 
Wildtype + 10.4 ± 0.8 14.6 ± 1.0***☨ 12.4 ± 1.0***☨ 
skMLCK-/- 6.7 ± 0.5 
1.4% 
7.4 ± 0.5 
12.2%‡ 
6.1  ± 0.4 
21.3%‡ 
skMLCK-/- + 6.8 ± 0.4 8.3 ± 0.5*** 7.4  ± 0.5*** 
Mean Concentric PTP (post-CS/pre-CS) 
Wildtype 1.0 
- 
1.30 ± 0.03***☨ 
10.0%‡ 
1.00 ± 0.30☨ 
20.0%‡ 
Wildtype + 1.0 1.40 ± 0.03***☨ 1.20 ± 0.03***☨ 
skMLCK-/- 1.0 
- 
1.11 ± 0.03*** 
10.0%‡ 
0.93  ± 0.04 
17.0%‡ 
skMLCK-/- + 1.0 1.21 ± 0.02
*** 1.10  ± 0.03*** 
Peak Concentric Force (mN) 
Wildtype 24.1 ± 2.4 
6.2%‡ 
31.7 ± 3.2***☨ 
9.1%‡ 
24.9 ± 2.4*** 
16.8%‡ 
Wildtype + 25.6 ± 2.2 34.6 ± 3.1***☨ 29.1 ± 2.6***☨ 
skMLCK-/- 17.6 ± 1.7 
4.5% 
20.7 ± 2.1*** 
8.2%‡ 
16.7  ± 1.5 
17.9%‡ 
skMLCK-/- + 18.4 ± 1.4 22.4 ± 1.7*** 19.7  ± 1.4** 
Peak Concentric PTP (post-CS/pre-CS) 
Wildtype 1.0 
- 
1.31 ± 0.03***☨ 
4.0%‡ 
1.04 ± 0.02* 
10.0%‡ 
Wildtype + 1.0 1.35 ± 0.03***☨ 1.14 ± 0.02**☨ 
skMLCK-/- 1.0 
- 
1.18 ± 0.02*** 
5.0%‡ 
0.96  ± 0.05 
14.0%‡ 
skMLCK-/- + 1.0 1.23 ± 0.04
*** 1.10  ± 0.03** 
Peak Tetanic Force (mN) 
Wildtype 226.3 ± 19.3 
9.9%‡ 
1.30 ± 0.03***☨ 
- 
1.00 ± 0.30☨ 
- 
Wildtype + 248.6 ± 21.5 1.40 ± 0.03***☨ 1.20 ± 0.03***☨ 
skMLCK-/- 177.0 ± 14.0 
12.5%‡ 
1.11 ± 0.03*** 
- 
0.93  ± 0.04 
- 
skMLCK-/- + 199.1 ± 15.1 1.21 ± 0.02
*** 1.10  ± 0.03*** 
Value are means ± SEM (n = 6 for tetanic data; n = 8 muscles for twitch force data); Mean force and peak 
force, twitch force determined by subtracting passive force from total twitch force at a given time point; 
*** indicates that value is significantly greater than unpotentiated value (Within Genotype, Holm-Sidak’s 
correction, P < 0.001), ** indicates that value is significantly greater than unpotentiated value (Within 
Genotype, Holm-Sidak’s correction, P < 0.01), ☨ Indicates that skMLCK-/- is significantly different than 
Wildtype at that time point (Between Genotype, Sidaks correction, P < 0.05), ‡ Indicates that epinephrine 
significantly enhanced value at that time point (Within Genotype, Sidak’s correction, P < 0.05). 
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5.3.2.2 Between Genotype Analysis 
 
A two-way ANOVA was used to determine the influence of epinephrine on mean 
concentric PTP between genotypes (wildtype vs. skMLCK-/-). This analysis determined a 
significant interaction between epinephrine treatment and genotype (P < 0.01). To this 
end, a follow-up test was then used to confirm where differences existed between 
genotypes (Table 4). This analysis revealed that following epinephrine incubation, 
wildtype muscles were significantly elevated above skMLCK-/- values at all time points 
(P < 0.05); with the exception of the final 8-minute value (P = 0.172).  
To determine if the ability to phosphorylate myosin RLC significantly affected the 
in vitro response to epinephrine incubation; the disparity between wildtype and skMLCK-
/- mean PTP values (Wildtype PTP value – skMLCK-/- PTP value) was analyzed in both 
conditions. Multiple un-paired t-tests were used to compare average disparity of PTP 
between genotypes from the control condition against the epinephrine condition. Full 
results for the average disparity of concentric PTP values are presented in Table 5 as 
means ± SEM. These data indicated that there was no point after the CS where the 
disparity between genotypes in the epinephrine condition was greater than that of the 
control condition. Moreover, to investigate how similar the responses of wildtype and 
skMLCK-/- muscles were to epinephrine - a linear regression (Figure 20) of the 13 post-
CS time points was conducted. Interestingly, results of the regression analysis 
demonstrated a very strong correlation between the responses of control to epinephrine 
treated muscle (r2 = 0.89).  
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Figure 20. Relative difference in twitch force between Wildtype and skMLCK-/- muscles with and without 
epinephrine incubation; values are means ± SEM (n = 13). Each point was calculated from the difference in 
PTP between Wildtype and skMLCK-/- muscles at that time; %Δ Control, derived from dividing Wildtype 
control PTP value from skMLCK-/- control PTP value at a given time point; %Δ Epinephrine, derived from 
dividing Wildtype epinephrine PTP value from skMLCK-/- epinephrine PTP value at a given time point. 
 
 
 
(PTP Difference EPI condition)T1 – (PTP Difference CON condition)T1 
= Δ relative effect of epinephrine 
 
Equation 2. The difference between PTP in the epinephrine condition and the control condition. This 
value indicates the effect of epinephrine between genotypes at a given time point (T), a value of 0 
represents epinephrine affects both genotypes equally i.e. both wildtype and skMLCK-/- muscles improved 
by 10%. 
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Table 5. The difference in concentric force potentiation between Wildtype and skMLCK-/- 
for both control and epinephrine treated EDL at 25°C 
 Condition  
Time Point (sec) Control Epinephrine 
%Δ 
(using Equation 1) 
5 18.2  ± 6.1% 17.6  ± 5.4% -0.6 
10 15.6  ± 6.5% 17.9  ± 5.4% 2.3 
15 17.0  ± 5.5% 17.8  ± 5.0% -0.8 
20 16.5 ± 5.8% 17.8 ± 5.0% 1.4 
30 18.2  ± 5.4% 19.3  ± 5.1% 1.2 
60 19.3  ± 4.9% 21.4  ± 4.1% 2.0 
120 19.2 ± 4.5% 19.5  ± 4.4% 0.2 
180 16.8  ± 4.5% 19.1  ± 3.3% 2.3 
240 15.8  ± 4.7% 17.4  ± 2.7% 1.5 
300 13.8  ± 4.8% 16.2  ± 3.1% 2.4 
360 13.3  ± 5.4% 16.5  ± 4.0% 3.2 
420 9.2 ± 5.2% 14.2  ± 3.1% 5.0 
480 7.7  ± 5.6% 11.3 ± 2.4% 3.6 
Value are means ± SEM where applicable (n = 8 muscles); Control, Derived from dividing Wildtype control 
PTP value from skMLCK-/- control PTP value at a given time point; Epinephrine, Derived from dividing 
Wildtype epinephrine PTP value from skMLCK-/- epinephrine PTP value at a given time point; %Δ, The 
difference of disparity between conditions determined using Equation 1; Analysis determined no 
statistically significant change after epinephrine treatment (un-paired t-test, Sidak-Bonferroni correction, P 
< 0.05).  
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5.4.3 Concentric Twitch Kinetics 
 
 Concentric twitch kinetics was analyzed at three representative time points before 
(unpotentiated) and after (peak and final) the potentiating stimulus. Measurements 
include time to peak tension (TPT), half-relaxation time (RT1/2), rate of force 
development (+dP/dt) and rate of relaxation (-dP/dt). Within group differences as a result 
of epinephrine administration were analyzed using a repeated measure ANOVA, while a 
series of unpaired t-tests were used to determine significant differences between 
genotypes at each time point. The results of this analysis as well as representative twitch 
traces for each major time point can be found below in Figure 21 and Table 6. 
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Figure 21. Absolute peak concentric twitch force traces (mN) from Wildtype from skMLCK-/- muscles 
before (A), 5 seconds after (B) and 8 minutes after (C) a conditioning stimulus (n = 8); Peak force, twitch 
force determined by subtracting passive force from total twitch force at a given time point; Green line, 
Denotes Wildtype epinephrine treated muscles; Blue line, Denotes skMLCK-/- epinephrine treated muscles; 
Black line, Denotes Wildtype control muscles; Red line, Denotes skMLCK-/- control muscles. 
A B 
 
C 
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Table 6. The effect of 1 μM epinephrine incubation on concentric twitch kinetics in 
Wildtype and skMLCK-/- mouse EDL at 25°C 
                    Potentiated 
Un-potentiated 5 Seconds    8 Minutes 
TPT (ms) 
               Wildtype 
               Wildtype +  
             skMLCK-/- 
             skMLCK-/-+ 
  
    13.8 ± 0.8 
    13.7 ± 0.6 
    12.8 ± 0.7 
    12.2 ± 0.7 
 
    15.5 ± 0.9               
    15.4 ± 1.0 
    13.4 ± 0.7 
    12.7 ± 0.6 
 
    14.6 ± 1.2               
    14.0 ± 0.8 
    11.4 ± 0.6 
    12.0 ± 0.5 
RT1/2 (ms) 
               Wildtype 
               Wildtype +  
             skMLCK-/- 
             skMLCK-/-+ 
  
    26.1 ± 2.2 
    26.1 ± 2.1 
    26.1 ± 2.1 
    26.4 ± 2.2 
 
    25.4 ± 2.1              
    25.3 ± 2.1 
    25.8 ± 2.1 
    26.1 ± 2.1 
 
    26.4 ± 2.2               
    26.0 ± 2.1 
    26.8 ± 2.2 
    26.5 ± 2.2 
+dP/dt (mNms-1) 
               Wildtype 
               Wildtype +  
               skMLCK-/- 
             skMLCK-/-+ 
  
    2.3 ± 0.3 
    2.6 ± 0.3* 
    2.2 ± 0.2 
    2.4 ± 0.2* 
 
    3.1 ± 0.3               
    3.4 ± 0.6* 
    2.6 ± 0.2 
    2.8 ± 0.3* 
 
    2.4 ± 0.3            
    3.0 ± 0.3* 
    2.0 ± 0.3 
    2.5 ± 0.3* 
-dP/dt (mNms-1) 
              Wildtype 
              Wildtype +  
              skMLCK-/- 
             skMLCK-/-+ 
  
    1.4 ± 0.2 
    1.4 ± 0.1 
    1.0 ± 0.1 
    1.1 ± 0.1 
 
    1.7 ± 0.2               
    1.8 ± 0.2 
    1.2 ± 0.2 
    1.3 ± 0.1 
 
    1.3 ± 0.2            
    1.4 ± 0.1* 
    1.0 ± 0.1 
    1.1 ± 0.1* 
Values are means ± SEM (n = 7). TPT, Time to peak tension; RT1/2, Half-relaxation time; +dP/dt, Rate of 
force development; -dP/dt, Rate of relaxation; +, Denotes the presence of epinephrine. * Indicates that 
epinephrine condition is significantly different than control at that time point (Within Genotype, Sidak’s 
correction, P < 0.05); ☨  Indicates that skMLCK-/- is significantly different than Wildtype at that time point 
(Between Genotype, un-paired t-test, two tailed, P < 0.05). 
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5.5.0 Myosin RLC Phosphorylation 
 
 It was initially hypothesized that wildtype muscles would exhibit greater myosin 
phosphorylation than skMLCK-/- muscles, and that epinephrine would significantly alter 
myosin RLC phosphorylation in wildtype muscles but not skMLCK-/-. A 2-way ANOVA 
was used to determine the difference in the effect of epinephrine on myosin RLC 
phosphorylation between genotypes (Table G.1). This analysis determined a main effect 
for time (P < 0.0001) but not for condition (P = 0.503). At no point was the level of 
myosin RLC phosphorylated significantly different between wildtype control and 
epinephrine conditions; however, a dunnet’s test revealed that myosin RLC 
phosphorylation was higher in the first 5 seconds after the CS, (P < 0.001) a value that 
remained elevated in epinephrine treated muscles (P < 0.05) but dissipated by 8-minutes 
in the control condition (Figure 22). Furthermore, muscles from skMLCK-/- mice had no 
detectable amounts of phosphorylated myosin; example western blots from all genotypes 
and conditions can be found in Figure 23. 
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Figure 22. The effect of time (x-axis) and epinephrine treatment on myosin RLC phosphorylation in 
Wildtype EDL at  rest, 5 seconds, and 8 minutes (n = 4-5); * Indicates significant increase from rest value 
(Within Genotype, dunnet’s test, P < 0.05), ** Indicates significant increase from rest value (Within 
Genotype, dunnet’s test, P < 0.001). 
  
66 
 
Figure 23. Cropped images from Appendix F, Urea/glycerol PAGE blots of myosin light chain 
phosphorylation in Wildtype (A) and (B) skMLCK-/- muscles from both control (CON) and epinephrine 
(EPI) conditions. Resting muscles from each group were frozen after a 30 minute equilibration period in 
either Tyrode’s solution or epinephrine bath, while stimulated muscles (5 sec and 8 min) were frozen 
within ~15 seconds of twitch. Negatively charged mono-phosphorylated (RLC-P) bands are identified 
based on specific increase in protein migration (Zhi et al., 2005) relative to non-phosphorylated (RLC). 
RLC-P content was manually determined using LI-COR software to analyze band densities; RLC, Denotes 
non-phosphorylated myosin RLC band; RLC-P, Denotes mono-phosphorylated myosin RLC band. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
67 
Discussion 
 
6.1.0 General Summary of Results and Findings 
 
This study is the first to directly examine the effects of epinephrine on concentric 
PTP and myosin phosphorylation over an 8-minute time course by utilizing skMLCK-/- 
mice as a negative control to parse out the effect of myosin phosphorylation. The purpose 
of this study was to test whether β-adrenergic stimulation augments the time-course and 
characteristics of concentric twitch potentiation, and if this is observed with alterations to 
myosin phosphorylation. To this end, we assessed concentric PTP, twitch kinetics, and 
myosin phosphorylation in both control and epinephrine (1 μM) treated muscles from 
wildtype and skMLCK-/- mice. The main findings of this project illustrated that the 
elimination of myosin RLC phosphorylation via gene ablation (skMLCK-/-) only has a 
small influence, and does not significantly alter the affect of epinephrine on concentric 
force potentiation (PTP), concentric force production (mN), or twitch kinetics (TPT, 
RT1/2, +dP/dt, -dP/dt). Furthermore, we predicted that epinephrine incubation would 
significantly alter myosin phosphorylation in wildtype mice. While, there is no evidence 
supporting the idea that epinephrine incubation significantly alters myosin RLC 
phosphorylation within 8 minutes of a conditioning stimulus in either wildtype or 
skMLCK-/- mice; epinephrine treatment did maintain phosphorylation values significantly 
above rest in wildtype muscles. Thus, it is likely that myosin RLC phosphorylation plays 
only a small secondary role in epinephrine-induced changes in muscle function and 
twitch characteristics over time.  
The following discussion explores these observations, and aims to justify the 
central finding that epinephrine incubation amplifies and maintains contractile 
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performance over time, in both the presence and absence of myosin phosphorylation. The 
observation that muscle twitch force and PTP are enhanced by epinephrine without 
significant alteration to myosin phosphorylation disagrees with the present hypothesis 
that epinephrine influences PTP by maintaining high levels of myosin phosphorylation 
(Decostre et al. 2000).  
6.2.0 Relation to Previous Studies 
 
 The work of Decostre et al. (2000) served as the background for this project. 
These researchers examined the effect of 1μM epinephrine on PTP and myosin RLC 
phosphorylation over 300 seconds. Interestingly, these researchers found that epinephrine 
enhanced isometric PTP ~15% and could maintain force production (8% PTP by 300 s) 
relative to control muscles. Our data confirms these findings from Decostre et al. (2000) 
and also suggests that the effects of epinephrine may be sensitive to factors such as 
contraction type (concentric > isometric) and time. In addition to contractile properties, 
Decostre et al. (2000) showed that myosin phosphorylation was maintained over 300 
seconds in the presence of epinephrine; our data also confirmed this finding. A 
comparison of their data juxtaposed our results (Figure 22) shows a strong similarity in 
the phosphorylation response to epinephrine over time, however not to the same degree. 
One reason for these differences between our data and previously published work may 
simply be the variance in time of measurement (300 s vs. 480 s), as myosin 
phosphorylation will inevitably decrease over time as a result of increased skMLCP 
activity (Stull et al., 2011); thus our data may have shown elevated RLC-P at 300 seconds 
in accordance with previous results. One reason for the differences could be that Decostre 
et al. (2000) conducted their experiments at 20°C, while our work was done at 25°C. This 
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is important, because as Mitsui et al. (1994) demonstrated that dephosphorylation of 
myosin is a highly temperature dependent process, wherein a difference of 5°C can result 
in a ~40% difference in myosin phosphorylation. To illustrate this, these researchers 
calculated the enzymatic rate constant and Q10 of protein phosphatases (the factor by 
which the rate constant increases by raising the temperature by 10) at 20 and 15 °C. The 
rate constants for dephosphorylation were 0.6 and 0.3 min-1 at 20 and 15°C, respectively, 
providing a Q10 of 5.1. These researchers concluded that these results support the idea 
that myosin phosphatase has high temperature dependence, and that this is responsible for 
higher steady-state force levels at low temperature. Thus, it is possible that the use of 
lower temperatures in previous work would promote a slowed rate of skMLCP, 
preserving myosin phosphorylation for longer.  
6.3.0 Contractile Mechanics of Wildtype and skMLCK-/- muscles 
6.3.1 The Effect of PTP on Concentric Force 
 
 6.3.1.1 Wildtype Muscles 
 
This study was the first to characterize the PTP time course of concentric twitches 
in both wildtype and skMLCK-/- muscles. Thus, the work regarding concentric twitches 
as well as skMLCK-/- mice is novel, juxtaposed previous literature.  Indeed, concentric 
PTP following a brief conditioning stimulus was observed in wildtype muscles, and at its 
peak value reached ~30% potentiation; a value which is nearly identical to previous 
reports (at 100 Hz) for concentric force (Gittings et al., 2014). Figure 19A shows that 
muscles from wildtype mice displayed enhanced potentiation as a result of the concentric 
paradigm. Our work also supports the case for a shortening-induced sensitization of the 
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PTP response relative to isometric twitch potentiation (Gittings et al., 2012; Caterini et 
al., 2011; Xeni, 2011).  
One prominent explanation for this observed phenomenon is to examine cross-
bridge cycling. For example, during submaximal stimulation the rate of cross-bridge 
detachment (gapp) is greater than the rate of cross-bridge attachment (fapp); thus cross-
bridge distribution generally favors a non-force generating state during shortening 
(Piazesi et al. 2007). However, any increase in fapp can cause large increases in the 
fraction of cross-bridges in the force generating state (αFs). As Sweeney and Stull (1990) 
demonstrated, the effect of calcium binding to troponin C changes the value of fapp, but 
not gapp, ultimately increasing the number of cross-bridges in the force generating state. 
Equation 3 depicts this theoretical framework suggested by Brenner (1988), and how it 
accounts for both the loss of absolute twitch force and a more noticeable effect of PTP in 
contrast to the isometric model. Furthermore, Sweeney and Stull (1990) point out that 
myosin phosphorylation will exert its effect on tension development by increasing fapp, 
without altering gapp; an effect which is more pronounced at low levels of calcium. 
Indeed, myosin phosphorylation plays a critical role in influencing the relationship 
between fapp and gapp (Sweeney and Stull, 1990) 
 
αFs = fapp/( fapp+ gapp) 
 [Ca2+]i =  fapp 
   αFs 
Equation 3. Theoretical framework for cross-bridges found in the force generating state (αFs); fapp, 
Denotes the rate of cross-bridge attachment; gapp, Denotes the rate of cross-bridge detachment. This 
equation depicts how increased [Ca2+]i will result in a greater rate of cross-bridge attachment, resulting in 
more cross-bridges in the force generating state. 
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 6.3.1.2 skMLCK-/- Muscles 
 
As previously discussed, this study is the first to characterize the concentric PTP 
time course of skMLCK-/- muscles. Interestingly, these muscles exhibited ~20% 
concentric force potention, results which are very similar to previous reported data using 
the same CS (4 x 100 Hz) to enhance twitch force (Gittings et al., 2014). On one hand, 
Zhi et al. (20005) noted that skMLCK-/- muscles do not display significant post-tetanic 
potentiation of isometric twitches; however, Gittings et al. (2014) have shown that 
skMLCK-/- muscles posses machinery capable of isometric PTP. Figure 19B indicates, 
post-tetanic potentiation of force occurred when we used concentric twitches in this 
study. This is in accordance with the speed-dependent properties and shortening 
sensitization of concentric PTP seen in wildtype muscles (Abbate et al., 2000; Gittings et 
al., 2012; Caterini et al., 2011; Xeni, 2011); as skMLCK-/- muscles are capable of 
undergoing Ca2+ induced changes to fapp and gapp. Like wildtype muscles, PTP in 
skMLCK-/- muscles is sensitive to both contraction type as well as changes to Ca2+ 
handling. However, simple comparison of the eight-minute time-course of concentric 
PTP (Figure 19) in the absence of epinephrine depicts stark baseline differences between 
the two genotypes. Specifically, this may come as a result of the inability of skMLCK-/- 
to phosphorylate myosin.  
Interestingly, both wildtype and skMLCK-/- (CON) reach peak potentiation by 
five seconds post-CS; by the 120 second mark, however, skMLCK-/- muscle force return 
to unpotentiated values, while the wildtype muscles were still potentiated by ~20% 
(Figure 19). The rapid dissipation of force in skMLCK-/- muscles is primarily a result of 
the inability to phosphorylate the RLC, however it may also indicate the loss of small 
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stimulation-induced increases in resting [Ca2+] observed by Smith et al., (2013). 
Moreover, while wildtype twitch force returned to baseline values by 480 seconds, the 
skMLCK-/- muscles continue to display a small but observable reduction in PTP of down 
to -6% relative to baseline. However, as Gittings et al., (2014) was able to demonstrate, 
this depression of normalized twitch force in skMLCK-/- control muscles may be fatigue 
related. A second consideration when observing the depressed force in skMLCK-/- 
muscles is the potential of cellular necrosis. However, this case is unlikely; as twitch 
force was recoverable after a 30-minute incubation between conditions. Moreover, 
unpublished observations from our lab have identified that dead muscles hardly respond 
to test pulses during incubation. Because all muscles are tested for a response before 
beginning experiments, it is improbable that they would begin to die after 300 seconds of 
experimental protocol.   
There is a clear difference in the dynamic force production capabilities of these 
two genotypes, possibly linked to the ability to phosphorylate the myosin RLC and 
increased fatigue resistance (Gittings et al., 2014; Cooper et al., 1988; Jones et al., 1982; 
Vandenboom and Houston, 1995). Over the eight-minute time course, a loss of 
potentiated force quickly manifests in the skMLCK-/- muscles. This response is evidence 
that without the skMLCK enzyme, these muscles are unable to phosphorylate myosin 
RLC and cannot maintain concentric twitch force potentiation as a result. The inability to 
maintain concentric PTP in the absence of myosin phosphorylation is a contribution of 
many factors. On one hand, skMLCK-/- muscles likely do not experience the same 
leftward shift of force-pCa relationship associated with myosin phosphorylation (Metzger 
et al.1989; Persechini et al., 1986; Sweeney and Stull, 1990) as do wildtype muscles. 
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Furthermore, skMLCK-/- muscles do not experience phosphorylation-dependent increases 
in fapp, without altering gapp (Sweeney and Stull, 1990). These observations show how our 
data help bolster previous reports regarding the effect of myosin phosphorylation on PTP; 
finding large differences in PTP between wildtype and skMLCK-/- muscles. 
6.4.0 Myosin RLC phosphorylation 
 
At rest, the amount of phosphorylated myosin of wildtype muscles in both the 
control and epinephrine treated conditions were very similar (within ~4%); a trend which 
coincides with previously published work (Decostre et al. 2003). Furthermore, these 
resting values for myosin RLC phosphorylation (~ 14 and 18%) were similar to values 
reported previously of  ~15% (Zhi et al. 2005). While our data did coincide with previous 
work, it was slightly elevated, reaching up to 21% in some samples. To explain this, it is 
important to note that the mishandling (pulling or stretching) of these muscles even 
slightly may induce release of Ca2+ in the muscle, in turn activating skMLCK and altering 
phosphorylation of myosin RLC. Thus, the resting values reported in our study may be 
even lower; however some physical manipulation may be responsible for the higher 
values found in some muscles. 
After stimulation (CS), wildtype muscles in both conditions displayed increased 
myosin RLC phosphorylation (~66% phosphorylation), values which remained 
significantly elevated ~23.5% above resting values over 480 seconds in epinephrine 
treated muscles. However, while the wildtype control condition was not significantly 
lower than the epinephrine treated muscles – they did not remain significantly elevated 
above resting values. Furthermore these peak-stimulated values measured at 5 seconds 
corroborate with published values of closer to 50% phosphorylation (Decostre et al. 2000; 
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Vandenboom et al., 2013), however our samples showed range from 40 to 80% 
phosphorylation. One explanation for the disparity between phosphorylation values may 
be rooted in the nature of skMLCK activation. As Stull et al., (2011) points out, the 
kinase is slow to activate, not peaking until some time (~10-15 s) after contraction takes 
place. Therefore any variation in freezing within this time window may yield difference 
in activation induced myosin phosphorylation. While our methods tried to replicate the 
same time frame from final twitch to freezing on each muscle (10-15 seconds); there is 
disparity between each sample. Thus, muscles that were frozen faster than others will 
likely be those which yield lower values, although this is only an assumption based on the 
work of Stull et al., (2011); as there is no record of the time taken to freeze each muscle.  
Another explanation for the differences in measured phosphorylation values is the 
presence of a non-specific band, which may affect the density of the RLC band. These 
bands can be found in several labs attempting to immunoblot for myosin RLC, as well as 
published works by Ryder et al., (2007). Zhi et al., (2005) point out how the density of 
observed bands can change by adding or removing bands via phosphatase treatment 
(Figure 24). There is an apparent increase in density of intermediate bands in samples 
that have undergone phosphatase treatment, potentially as a result of limited proteolysis 
of the nonphosphorylated RLC. In the instance of our observations, while not caused by 
the use of dephosphorylation treatment, the extra abundance of protein  (non-specific 
band) may interfere with the proteolysis of the bands present. Another potential 
consideration is that the dense signal produced by the non-specific bands may dampen the 
intensity of the non-phosphorylated bands, especially in stimulated samples where the 
non-phosphorylated band would be less intense than at rest. After observing the non-
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specific band and it’s affects on the observed myosin phosphorylation; a set of side 
experiments were conducted in an attempt at defining this band (Appendix E) and 
determining its origin. While these experiments were not able to conclusively pinpoint 
the cause of the band, several characteristics were established. For instance, this band is 
not a result of mechanical over homogenization, nor is it a result of over dilution with 
sample buffer. Furthermore, under-dilution of primary anti-body did not affect non-
specific binding in this case; nor was the secondary anti-body nonspecifically binding to 
any proteins. The full set of experiments for determining the cause and characteristics of 
the observed non-specific band can be found in Appendix E. 
We observed that phosphorylated myosin RLC content was eliminated in resting 
skMLCK-/- muscle as expected, as well as most stimulated samples. These muscles 
generally showed no measureable RLC phosphorylation in response to the high frequency 
conditioning stimulus, however previous work has detected up to ~5% phosphorylation in 
these muscles (Zhi et al. 2005); a result which had been detected in our work as well and 
can be seen in Appendix F. Zhi et al, (2005) identified the monophosphorylated band in 
skMLCK-/- muscles when muscle homogenates were prepared in a non-denaturing buffer 
without protein phosphatase inhibitors; confirming that the band in question was in fact a 
result of phosphorylation (Figure 24). Analysis of the purified monophosphorylated RLC 
from skMLCK-/- muscles led to detection of peptides that cover >95% sequence of the 
protein (Zhi et al., 2005; Figure 25). Furthermore, collision-induced fragmentation 
spectrum (MS/MS) determined that the phosphorylation site at residue serine 15, adjacent 
to the site phosphorylated by skMLCK (Stull et al., 1986). These results suggest that 
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another kinase, not activated by contraction, may be responsible for the phosphorylation 
of the unknown middle band. 
 
Figure 24. Separation of non-phosphorylated (RLC) and phosphorylated (RLC-P) RLC 
by urea/glycerol-PAGE. Results are presented without (-) or with (+) dephosphorylation 
treatment (Zhi et al., 2005). Results indicated that when dephosphorylation was not 
inhibited (+), muscle samples did not contain an RLC-P band; thus the band was a result 
of phosphorylation and is the mono-phosphorylated RLC.  
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Figure 25. Collision-induced fragmentation spectrum of the phosphorylated peptide from RLC. 
The spectrum of AGAEGpSSNVFSMFDQTQIQEFK shows that serine (Yamaguchi et al., 2004) 
in mouse skeletal muscle RLC (MLC2F) is phosphorylated. The b and y designate the N- and C-
terminal fragments of the peptide produced by breakage at the peptide bond in LTQ, respectively. 
The number represents the residue number from either the N or C terminus. * , Those daughter 
ions with loss of 98-Da peaks. 
Interestingly, Zhi et al., (2005) also detected an intermediate band between the 
non-phosphorylated and monophosphorylated RLCs (Figure 24); the identity of the band 
is unclear, however represents < 5% of total immunoreactivity and does not change with 
stimulation. This unknown intermediate band is not the same band as identified by our 
lab (Appendix E), and is a result of phosphorylation – not non-specific binding. Our lab 
has previously detected small quantifiable amounts of monophosphorylation in skMLCK-
/- muscles via this non-specific kinase (Gittings et al., 2015); however, this result is not 
always achievable. Possible explanations for this lie in the sensitivity and subjectivity of 
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the methods. While our lab uses the same methods as presented in both Zhi et al., (2005) 
and Ryder et al., (2007), including polyclonal antibodies raised in rabbits to purified 
skeletal and cardiac RLC; there is still room for variability when western blotting for 
RLC.  For example, sample preparation (i.e., preparing 10X transfer buffer and diluting 
stock solutions), homogenization (ensuring that muscles are denatured before glass 
homogenization and adequately purified), protein transfer (guaranteeing the optimal pH 
of transfer buffer, equilibration of gels and membranes, and reduction of air bubbles), 
separation (adequate sucrose saturation, protein content, and removal of air bubbles), and 
imaging. One major example could be that samples were either over, or under saturated 
with urea (a process that is completely subjective, see Methods); a substance used for 
protein denaturing by breaking hydrogen bonds during the sample preparation (Bennion 
and Daggett, 2003). Under-saturation could result in insufficient breakdown and lack of 
the very small phosphorylated band, while over saturation could cause too much 
denaturation to the band; making it even less detectable.  
One way to improve the repeatability of results with urea saturation would be to 
standardize using urea crystals. Methods from the lab of James Stull suggest using urea 
crystals, which are all standardized to the same weight. In doing so, one can keep track of 
how many crystals have been added to the sample instead of roughly how many scoops of 
urea. The variability of these methods, such have been tested to determine their effects on 
the resulting band density and presentation in Appendix E. However, this process is still 
difficult without knowing the amount of protein contained in each sample; thus 
standardizing the amount of protein loaded into each sample via protein assay may prove 
the biggest help. To do this, our lab has done an optimal loading analysis found in 
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Appendix E using Bradford assay and western blot techniques. Whatever the cause for 
the lack of resting phosphorylation observed in skMLCK-/- muscles, the ability for 
skMLCK to phosphorylate myosin is still accounted for and the measurable difference 
between conditions still remains a point of interest. Certainly, the effect of skMLCK gene 
ablation is clear – further substantiating the use of skMLCK-/- controls to account for the 
effect of RLC phosphorylation.  
 The present results provide no evidence to support any effect of epinephrine on 
skMLCK function, and alterations to myosin RLC phosphorylation. At no point was a 
significant difference in myosin RLC phosphorylation observed between wildtype control 
and epinephrine groups, strongly suggesting that at anytime before or after a CS; 
epinephrine did not alter function of either the skMLCK. However, the maintenance of 
RLC phosphorylation above resting values seen in epinephrine treated wildtype muscles 
may suggest a small influence of epinephrine on the skMLCP enzyme over time. These 
observations support altered Ca2+ handling instead of changes to myosin phosphorylation 
as a primary, but not only, mechanism for epinephrine’s effect on muscle contractile 
function (Kraemer et al., 2007).  
6.4.1 Ca2+ Based Mechanisms for Potentiation 
 
There is strong evidence correlating myosin phosphorylation with twitch 
potentiation (Manning and Stull 1979; Moore et al., 1990; Palmer and Moore 1989; 
Vandenboom et al., 1995, 1997) and while it is a focal point of this discussion, alternative 
mechanisms for potentiation must also be considered. While there have been other 
considerations for the cause of PTP in the past, such as K+ potentiation (Liley and North, 
1953), Ca2+ is now regarded as the most likely alternative. Described as a secondary 
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mechanism for potentiation (Vandenboom et al. 2013), stimulation-induced alterations to 
resting Ca2+ levels account for observed twitch potentiation in the absence of RLC 
phosphorylation (Smith et al., 2013). In fact, research utilizing the mouse lumbrical has 
discovered that these muscles do not phosphorylate the RLC (Ryder et al. 2007; Smith et 
al. 2013). Much like the skMLCK-/- muscles used in this project, these researchers 
observed a short-lived (~30 seconds) potentiation of force that was temporally coupled 
with an increased resting myoplasmic [Ca2+]. Stimulation-induced alterations to resting 
Ca2+ are proposed to enhance force through thin filament activation, by binding 
myoplasmic Ca2+ and causing a greater [Ca2+] occupancy of Troponin C (TnC) 
(McKillop and Geeves, 1993; Maytum et al., 1999). Although this project did not assess 
myoplasmic [Ca2+], data from our skMLCK-/- control muscles, which show transient 
twitch force potentiation for ~30 seconds in the absence of myosin phosphorylation, 
indicates similar trends to Smith et al. (2013). As such, comparisons can be made 
concerning the role of Ca2+ potentiation as a contributing factor to the PTP we observed 
in skMLCK-/- muscle (Gittings et al., 2014). Moreover, stimulation-induced alterations to 
resting Ca2+ are present regardless of genotype. Consequently, thin filament activation 
occurs in both wildtype and sMLCK-/-; thus the disparity between the PTP values in 
skMLCK-/- and wildtype muscles (Table 5) will indicate the PTP contribution of 
skMLCK-mediated RLC phosphorylation independently. 
 
 
 
 
  
81 
6.5.0 The Effect of Epinephrine on Force Production 
6.5.1 Inotropic Effects of Epinephrine  
 
The positive inotropic effects in fast skeletal muscle following adrenergic receptor 
stimulation have been reported in many studies (Cairns & Dulhunty, 1993 a; Cairns et al. 
1993). The enhancement of isometric twitch force is small, but observable after β-
adrenergic stimulation (Tashiro, 1973; Cairns & Dulhunty, 1993 a; Cairns et al. 1993; Liu 
et al. 1997; Decostre et al. 2000; Andersson et al. 2012). These researchers have 
established a link between changes in Ca2+ handling and isometric force potentiation. 
Using fluorescent Ca2+ indicator (Indo-1), Cairns et al. (1993) have shown β-adrenergic 
stimulation increased [Ca2+]i  linearly with tension at 30Hz and 100Hz. However, these 
researchers also determined that during 100 Hz stimulation β-adrenergic agonists did not 
increase the rate of [Ca2+]i  release, nor did it slow the SR Ca
2+ re-uptake. In addition to 
replicating the effect of increased peak [Ca2+]i  - Liu et al. (1997) also determined that 
phosphorylation of phospholamban was not the mechanism of the slowed twitch response 
in fast twitch muscle, as they are not regulated using phospholamban. In the de-
phosphorylated state, phospholamban is responsible for the inhibition of the SERCA Ca2+ 
pump; however phosphorylation via PKA or CaM-kinase after β-adrenergic stimulation 
will abolish this inhibition (Martin, 2000). Most recently, the work of Andersson et al. 
(2012) has shown β-adrenergic stimulation to increase both peak amplitude and time to 
peak amplitude of  [Ca2+]i . These findings regarding Ca
2+ transients and the positive 
inotropic effect in fast skeletal muscle provide a basis for discussion regarding our 
results; particularly as an explanation for how skMLCK-/- muscles respond to epinephrine 
treatment.  
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The finding that epinephrine elicits the same changes to the contractile parameters 
of both wildtype and skMLCK-/- muscles (depicted in Figure 20) implies that a 
mechanism other than myosin RLC phosphorylation is primarily responsible for 
epinephrine’s action. It was initially proposed by Decostre et al. (2000) that epinephrine 
maintained high levels of RLC phosphorylation by inhibiting skMLCP activity; while 
skMLCP activity was not measured, the data provided by myosin phosphorylation and 
PTP can help us speculate on the role of this enzyme. In fact, because epinephrine 
maintained wildtype myosin phosphorylation above resting values by 8-minutes post-CS 
(Figure 22), a case can be made for the small role that myosin RLC plays in 
epinephrine’s influence on PTP over time. Furthermore, recent evidence elucidates PKA-
induced phosphorylation of a single amino acid of the RyR1, S2844, as a downstream 
target of β2-adrenoceptor activation for increased SR Ca2+ release. This mechanism has 
been discussed by Andersson et al. (2012), who concluded that the ablation of S2844 site 
on RyR1 links excitation contraction coupling and adrenergic stimulation mediated 
increases in force. This may explain why skMLCK-/- muscles, while missing the 
skMLCK enzyme (Gittings et al., 2011) have virtually the same response to epinephrine 
as wildtype muscles. Although myoplasmic calcium was not measured in this study, the 
ablation of the skMLCK gene allows some conclusions to be drawn about the role of 
calcium-induced changes in function. Thus, because we assume the changes to calcium 
handling are the only other primary source of PTP modulation other than myosin 
phosphorylation, using differences in PTP between genotypes, the contributions from 
myosin phosphorylation can be separated from the effect of altered calcium signaling. 
This method gives a good estimate for the role of both calcium and myosin 
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phosphorylation. Quantification of changes to calcium transients during β-adrenergic 
stimulation between these genotypes will help to substantiate this claim.  
Assuming that the only difference between wildtype and skMLCK-/- muscles is 
the contribution of myosin RLC phosphorylation, the robust correlation observed for the 
effect of epinephrine between genotypes is likely a result of a shared mechanism. In this 
respect,  the β-adrenergic and SR RyR1 receptor phosphorylation is a possibility. Table 5 
illustrates that while the PTP attributed to RLC phosphorylation was anywhere from ~9 
to 19% (CON) at any given time, it accounted for only a small difference (~5%) in 
potentiation in the presence of epinephrine at any point after the CS. These data provide 
evidence that myosin RLC phosphorylation is responsible for the difference in PTP 
observed between genotypes, but plays a very small role in the effect of β-adrenergic 
stimulation; an effect which may become more important as time goes on. 
6.6.0 The Epinephrine-Induced Maintenance of Concentric PTP 
 
This study reports significant evidence corroborating the prolongation effect of 
epinephrine on PTP as originally observed by Decostre et al. (2000).  In their study, 
isometric twitch potentiation was maintained for several minutes, with no change to 
unpotentiated twitch force production as a result of epinephrine treatment. The current 
project successfully replicated this effect using dynamic contractions and for a greater 
period of time (8 vs. 5 min). We also determined a significant influence on unpotentiated 
force, thus suggesting that the concentric model is a more robust model for the 
observation of epinephrine-induced changes to force production. It is apparent that 
epinephrine significantly alters PTP, both in terms of magnitude and time-course at any 
point after a CS. Therefore, while the PTP prolongation effects of epinephrine are not as 
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robust in skMLCK-/- muscles, the ability to potentiate force above pre-CS values remains 
for 480 seconds. The most likely explanation for the ‘new’ ability of epinephrine-induced 
PTP maintenance is two-fold.  
First, any adequate explanation for the major contributor to this effect would have 
to account for a shared mechanism between both wildtype and skMLCK-/- muscles. Thus, 
the evidence suggests that epinephrine may enhance and prolong the calcium-induced 
potentiation described by Smith et al. (2013); a theory that is corroborated with evidence 
presented by Andersson et al. (2012). Smith et al. (2013) proposed that in the absence of 
any myosin RLC phosphorylation-mediated increase in Ca2+ sensitivity, that Ca2+ 
activation of the thin filament may be increased for a short duration (~30 seconds). One 
way this is possible is through saturation of the intracellular Ca2+ buffer protein 
parvalbumin, allowing for a greater fraction of free Ca2+ released from the SR to bind to 
TnC on actin. This has also been suggested by Cairns et al. (1993) to happen after high-
frequency (100 Hz) stimulation as a result of β-agonist induced increases in [Ca2+]i.  
In addition to the potential of epinephrine to bolster Ca2+ release, further 
consideration can be given to the ability of epinephrine to slow the re-uptake of 
myoplasmic Ca2+ by reducing SERCA activity ~20% (Batts et al., 2007), resulting in 
even greater prolonging of Ca2+ buffer saturation. The results presented by Batts et al. 
(2007) makes a case for not only why acute epinephrine treatment would delay Ca2+ re-
uptake, but also why these effects make be more pronounced at the end stages of the 
time-course (i.e., after 300 seconds). Given this, the reduced Ca2+ uptake rates reported 
by Batts et al. (2007) are consistent with the slowing effects of epinephrine on relaxation 
of fast muscle and the interaction between epinephrine incubation and depressed SR 
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function may be linked to depressed Ca2+-ATPase activity seen with fatigue (Batts et al., 
2007). While relaxation kinetics are dependent on more than just Ca2+ sequestration, this 
connection gives support to the idea that epinephrine slows Ca2+ re-uptake, and may 
explain why epinephrine seems to have more robust effects on the time-course of mean 
twitch force.  
 As previously mentioned, while the observed effect of epinephrine between 
genotypes is very similar, the ability to prolong PTP is slightly less robust in skMLCK-/- 
as wildtype muscle and therefore must be a result of inability to phosphorylate myosin. 
Thus, the small observable difference in the effect of epinephrine is most likely to be 
attributed to a pathway only present in wildtype muscles, in this case the ability to 
phosphorylate myosin via skMLCK.  The data presented supports this, and points to 
epinephrine as having what seems to be a mild mediation of myosin phosphorylation that 
grows over time. While we did not directly measure the activity of either skMLCK or 
skMLCP, the findings of this study supports some conclusions made by Decostre et al. 
(2000) about the effect of epinephrine on myosin RLC. Our results corroborates the 
observation that epinephrine incubation does not alter resting myosin RLC 
phosphorylation in wildtype muscles, nor does it significantly affect peak levels of RLC 
phosphorylation after stimulation. These findings indirectly indicate that epinephrine 
does not activate either skMLCK (Manning and Stull, 1982; Decostre et al. 2000), and 
supports the observation that cAMP-dependent PKA phosphorylation has no direct effect 
on skMLCK (Edelman and Krebs, 1982). Moreover, it is uncertain how β-agonist 
stimulation would enhance Ca2+ release (Andersson et al., 2012) without increasing 
myosin phosphorylation; as the skMLCK is a Ca2+/Calmodulin dependent kinase 
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(Sweeney et al., 1993). Consequently, the mechanistic pathway for epinephrine’s affect 
on myosin RLC phosphorylation still remains unclear, however future work aimed at 
quantifying enzyme activity during these events would elucidate a more definitive role 
for epinephrine.  
6.7.0 Effect of Epinephrine on Twitch Kinetics 
6.7.1 Rate of Force Development (+dP/dt) and Time to Peak Tension (TPT) 
 
 The present findings indicate that epinephrine enhances rate of concentric force 
development (mN/ms) before and after a high-frequency conditioning stimulus. Previous 
research has observed a range of changes to the temporal parameters of isometric 
twitches (Brown et al. 1948; Bowman and Ziamis, 1958; Andersson et al., 2012). 
However, the ability of epinephrine to significantly elevate +dP/dt above that of a control 
group was only reported at 300 seconds after a conditioning stimulus (Decostre et al., 
2000); where as Andersson et al. (2012) observed a robust 30% increase in +dP/dt using 
the β-agonist Isoprenaline. This may suggest variability caused by the use of different β-
agonist compounds, as well as stimulation paradigm. The present findings indicate that 
epinephrine will enhance the rate of force development of potentiated twitches 
significantly for as long as 8-minutes (P < 0.0001). This finding has significant 
implication regarding contractile performance in vivo, highlighting that epinephrine can 
result in changes to muscle force, work and power which helps animals better cope with 
stressful situations. The data presented in Table 6 show that  +dP/dt is augmented by 
epinephrine in both genotypes across all time points; and as such is evidence that the 
mechanism regulating the effects of epinephrine on the rate of force development exists 
in the absence of myosin RLC phosphorylation. Thus, an RLC independent mechanism is 
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responsible and increased Ca2+ activation of the thin filament may be the most likely 
cause of this effect.  
 Our data suggest that epinephrine treatment of muscles results in increased rates 
of force development, however due to the equally elevated forces (i.e., 10% increase to 
both measures); the time to peak tension is relatively unchanged. This reinforces the idea 
that rate of force development and twitch force are positively correlated (Vandenboom, 
Grange, & Houston, 1995) and also explains why epinephrine treatment does not 
significantly lower TPT in the presence (wildtype) or absence (skMLCK-/-) of myosin 
phosphorylation. 
6.7.2 Rate of Relaxation (-dP/dt) and Half Relaxation Time (RT1/2) 
 
 Epinephrine administration had no definitive effect on the relaxation kinetics of 
either wildtype or skMLCK-/- muscles within 5 seconds post-CS (Table 6). However, 
after 8 minutes, a small but significant decrease in -dP/dt is observed. The reverse affect 
is often seen in slow-twitch muscles as a result of phospholamban phosphorylation, and is 
regarded as the positive lusitropic effect (Cairns & Borrani, 2015). In contrast, Cairns and 
Borrani (2015) point out that fast-twitch mammalian muscles can exhibit a slowed 
relaxation which can be linked to altered Ca2+ re-uptake (Al-Jeboory & Marshall, 1978; 
Bowman & Ziamis, 1958; Bowman & Nott, 1970). The link between the presence of 
phospholamban and abbreviated relaxation times is important to note, as it helps to 
explain why fast twitch muscle have increased relaxation times. For example, it is 
established that β2-adrenergic stimulation leads to a greater influx of Ca2+ into the 
myoplasm (Cairns & Borrani, 2015; Andersson et al., 2012). However, because fast 
twitch muscles do not posses the machinery; such as phosphorylation of phospholamban 
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(Liu et al. 1997; Vangheluwe et al. 2005) – they may not be able to deal with the 
increased Ca2+ re-uptake load caused by epinephrine treatment. Thus, as a result, it takes 
longer for fast twitch muscles re-uptake Ca2+ back into the sarcoplasmic reticulum, 
leading to longer relaxation times. In addition, epinephrine has the ability to slow the re-
uptake of myoplasmic Ca2+ by reducing SERCA activity (Batts et al., 2007); resulting in 
even greater prolongation of Ca2+ buffer saturation, and thus increased relaxation times. 
The significance of this consideration is that the longer relaxation times can lead to 
increased mean force of twitches – as altering the kinetics following a twitches peak will 
increased average force. Thus, the use of mean twitch force in this study gives an idea for 
both changes in calcium efflux, as well as calcium re-uptake. 
  As discussed earlier, the effect of β-agonists on twitch kinetics have not been 
entirely conclusive. While previous work has found epinephrine to significantly alter 
half-relaxation time of isometric twitches by up to 25% (Decostre et al., 2000; Bowman 
and Ziamis, 1958), others have suggested no change (Andersson et al., 2012). However, it 
is important to consider that due to the novelty of concentric twitches used in this study, 
comparisons to research citing isometric kinetics may be difficult. For example, as this 
study points out (i) potentiating twitch force could potentially alter how sensitive the 
contractile apparatus response is to epinephrine (concentric > isometric). Furthermore, 
concentric twitches yield lower forces than isometric, which may display less profound 
changes to twitch kinetics. For example Gittings et al. (2011) points out that the same 
conditioning stimulus can significantly alter isometric twitch kinetics, while not changing 
concentric kinetics. Thus, a difference exists between contraction types with regard to 
susceptibility to change. 
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6.8.0   Limitations 
 
The observations and conclusions of our research are principally limited to fast 
twitch mammalian skeletal muscle in carefully controlled in vitro conditions. Wildtype 
mice used in this experiment were not littermates of the skMLCK-/- knockout mice. 
Holmdahl & Malissen (2012) stress the importance of littermate controls for 
environmental and genetic variability. Our experiments however, do attempt to control 
for Holmdahl & Malissen’s (2012) variable factors: cage, age, sex (see Methods). The 
mouse extensor digitorum longus (EDL) muscle was chosen as a representative fast 
twitch muscle (Figure 9), as it is almost exclusively comprised of fast myosin isoforms 
that display RLC phosphorylation and force potentiation (Vandenboom et al., 2013): 
8.6% type IIA, 30.3% type IIX, and 59.7% type IIB (Gittings et al., 2011). Thus, mouse 
EDL muscle is considered homogeneous in nature, and extrapolating the physiological 
role of adrenaline on RLC phosphorylation to larger, heterogeneous muscles may be 
problematic. We were also limited by the assumption that the signaling cascade for 
epinephrine is the same in both wildtype and skMLCK/- mice, such that in both genotypes 
epinephrine inhibits the activity of skMLCP. In vivo muscle activity is not accurately 
approximated by concentric contractions, as physiological contractile performance is 
highly dependent on muscle length. Furthermore, the physiological applicability of these 
results were not conclusive; due to the fact that in an effort to maintain the viability of 
EDL muscles, the proposed in vitro experiments are conducted at sub-physiological 
temperatures (25C). 
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Conclusions and Significance 
 
7.1.0 Primary Findings 
 
 skMLCK-/- knockout mouse EDL muscles showed virtually no detectable myosin 
RLC phosphorylation and did not change with stimulation or epinephrine 
incubation. 
 
 Myosin RLC phosphorylation in wildtype muscles significantly increased 5 
seconds after a conditioning stimulus to a peak 65.9% phosphorylation in the 
control condition, and to 66.3% in the epinephrine condition. 
 
 Myosin RLC phosphorylation was significantly maintained above resting values 
by 8-minutes post-CS in the epinephrine treated condition. The presence or 
absence of myosin RLC phosphorylation was not a major influence on the relative 
effect of epinephrine on concentric PTP (r2=0.895). 
 
 Potentiated concentric force was elevated by epinephrine in wildtype muscles. 
The absence of myosin RLC phosphorylation did not remove the PTP effect in 
skMLCK-/- knockout muscles, however they exhibited significantly less 
concentric potentiation (CON ~12%; EPI ~19% at 5 seconds post-CS) than 
wildtype. 
 
 Rate of force development (+dF/dt) was elevated up to in both genotypes by 
epinephrine; this effect was slightly more prominent before the CS (+4%) and 5 
seconds after (+2.5%) in wildtype muscles. 
 
 Epinephrine may be most reliant on pathways outside of the myosin RLC, and 
may only attribute a small portion of the PTP maintenance effect to RLC 
phosphorylation (up to 5~% after 300 seconds). Altered Ca2+ handling may be 
responsible for the majority of change in the first 5 minutes following stimulation. 
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7.2.0 Significance of Findings 
 
 The purpose of the study at hand was to determine whether epinephrine enhances 
concentric PTP primarily by prolonging or elevating myosin phosphorylation over time 
following stimulation. The inability to phosphorylate myosin RLC in skMLCK-/- muscles 
provided a crucial experimental control in elucidating the nature of epinephrine-induced 
alterations to concentric force via RLC phosphorylation. The results indicate that the 
absence of myosin RLC phosphorylation significantly alters concentric PTP, but does not 
decisively modify the effects of epinephrine on concentric twitch force or its 
characteristics. This effect of epinephrine on concentric PTP is very similar between 
wildtype and skMLCK-/- muscles. Although the presence of myosin phosphorylation 
“boosts” the absolute difference in concentric PTP, there is only a small disparity in 
relative effect that exists after roughly 240 seconds; this may indicate that myosin RLC 
phosphorylation acts to preserves epinephrine’s effect on concentric PTP as time elapses. 
Therefore, while it seems myosin RLC phosphorylation may slightly aid the prolongation 
of concentric PTP – the primary mechanism of epinephrine-induced alteration of 
concentric force production is available in the absence of RLC phosphorylation. The 
observation that myosin RLC phosphorylation was unaltered during epinephrine-
enhanced PTP also helps to further elucidate a mechanistic explanation for β-adrenergic 
stimulation, PTP and contractile function. Previous investigation has suggested 
epinephrine prolongs PTP primarily as a function of enhanced RLC phosphorylation, via 
skMLCP inhibition. While epinephrine didn’t significantly raise myosin phosphorylation 
in wildtype muscles, we did note the maintenance of RLC phosphorylation with 
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epinephrine after 480 seconds, a finding that implicates the RLC as a small accessory in a 
much larger cascade of cellular signaling. 
 The results of the present study provides strong evidence that acute β-adrenergic 
stimulation can prolong and amplify concentric PTP over long periods of time. In 
addition, these results show that epinephrine enhances virtually all characteristics of force 
production, and becomes more pronounced over time – indicating an immediate 
amplification of force, as well as the potential for long-term fatigue resistance. This 
finding suggests improved contractile performance and a better ability to cope with 
stressful situations in vivo, where even small changes to twitch force can result in 
substantial gains in muscle force, work and power in the living animal. A primary 
objective of this project was to begin to identify possible mechanisms of action for 
epinephrine on both contractile function and PTP. The interpretation of the present study 
is that epinephrine alters the mechanical function of muscle primarily by increasing 
myoplasmic calcium levels, resulting in increased thin filament activation. This 
explanation would account for the observations in the absence of myosin RLC 
phosphorylation, while still rationalizing the enhanced magnitude of PTP in wildtype 
muscles.   
This study produced several novel findings regarding the effect of β-adrenergic 
stimulation on concentric PTP and dynamic twitch characteristics using skMLCK-/- 
controls. Before now, it was clear that myosin RLC phosphorylation was a critical 
mechanism to PTP and that epinephrine altered the potentiated state. Using gene ablation 
in combination with a time course of a functional dynamic twitch, we have begun to 
bridge the gap between the interactions of these two elements. These findings better the 
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understanding of the mechanisms underlying epinephrine’s function, and provide a more 
detailed insight into a link between β-adrenergic stimulation and in vivo muscle function. 
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7.3.0 Future Research & Considerations 
 
 The following research questions would help to verify and improve upon the 
present findings, as well as provide scientific basis for continued investigation of β-
adrenergic stimulation and muscle physiology in vitro. 
 
 Does epinephrine significantly alter the concentric PTP time-course in the 
absence of skeletal muscle myosin light chain phosphatase (skMLCP)? 
 
 Does β2-adrenergic stimulation alter skeletal muscle myosin light chain 
phosphatase (skMLCP) activity after a conditioning stimulus in mouse EDL? 
Does this effect dissipate despite the persistence of PTP? 
 
 What is the effect of β2-adrenergic stimulation on low-frequency (stair-case) 
potentiation? Does stimulation pattern change the observed effect of epinephrine-
induced alteration of force? 
 
 Does epinephrine incubation enhance calcium release during PTP through PKA 
mediated phosphorylation of RyR1? Is resting calcium significantly altered in 
RyR1-S2844A mice? 
 
 Will chronic exposure to stress alter the prolonging effects of β2-adrenergic 
stimulation on concentric PTP? Is RyR1 receptor desensitization responsible? 
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Appendix A: Tyrode’s Solution and Surgical Anaesthetic 
 
Table A.1. Surgical Anesthetic 
 Anesthetic 
Drug Name Sodium Pentobarbital 
Concentration Stock 240 mg/mL 
Concentration Working 4.8 mg/mL 
Drug Dose (mg/kg) 60  
Administration IP Injection 
Average Volume Used 0.25 
Needle Gauge 23 
Timing of Administration Prior to Surgery 
 
 
 
 
 
Table A.2. Stock solutions for Tyrode Solution (mixture of stock A and stock B). 
Compound Nomenclature Concentration (mM) 
Stock A 
Sodium Chloride NaCl 121 
Potassium Chloride KCl 5 
Sodium Bicarbonate NaHCO3 24 
D-Glucose C4H12O4 5.5 
Sodium Hydrogen Phosphate NaH2PO4 0.4 
Magnesium Chloride MgCl 0.5 
EDTA  0.1 
Stock B 
Calcium Chloride CaCl 1.8 
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Appendix B: Surgical Removal/EDL mounting 
 
 
 
Figure B.1. Initial incisions on medial and lateral aspect of distal insertion of EDL 
muscle 
 
 
 
Figure B.2. Use of silk suture to tie off distal portion of EDL muscle in preparation for 
removal 
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Figure B.3. Use of silk suture to tie-off proximal aspect of EDL muscle in preparation for 
removal and mounting in organ bath 
 
 
 
 
Figure B.4. Mounting newly removed EDL muscle into cold bath of Tyrode’s solution in 
preparation for transfer into experimental organ bath 
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Appendix C: Bradford Reagents 
 
Materials & Apparatus 
 
 Bovine serum albumin (BSA) 
 Protein assay dye reagent concentrate 
 Skirted microtiter 96–well plate 
 Spectrophotometer 
 
Reagents 
 
1. Stock BSA Solution (1 mg/mL) 
 
 100 g bovine serum albumin 
 DDH2O (100 mL final volume) 
o Aliquot into eppendorf tubes for individual trials 
 Store at –20° C and thaw before use 
 
2. Stock Protein Assay Dye Reagent (1:4 dilution) 
 
o 20 mL concentrated colorimetric assay dye 
o 80 mL DDH2O 
o Store at 4° C 
 
Standard Curve Preparation 
1. Prepare whole homogenate sample fresh the day of experiment. 
2. Remove one aliquoted sample of 1 mg/mL stock BSA solution from storage. 
3. Prepare all BSA standard solutions and store in eppendorf tubes on ice. 
Table C.1. Volumes of Stock BSA Solution and DDH2O required for the preparation of 
Bradford protein assay standard solutions. 
 
Protein Concentration 
(mg/mL) 
Stock BSA Solution 
(μL) 
DDH2O 
(μL) 
1 1000 0 
0.5 500 (from 1 mg/mL) 500 
0.25 500 (from 0.5 mg/mL) 500 
0.125 500 (from 0.25 mg/mL) 500 
0.05 100 (from 0.5 mg/mL) 900 
0 0 1000 
*BSA (bovine serum albumin) 
*DDH2O (double distilled water). 
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Sample Preparation 
4. Gather all samples to be analyzed for protein quantification. 
5. Prepare 10–fold dilutions for all samples by loading individual eppendorf tubes 
with 10 μL of whole homogenate and 90 μL of DDH2O. 
6. Return whole homogenates to –80° C storage, and place diluted samples on ice. 
Bradford Protein Assay 
7. Wash a 96–well plate thoroughly in order to ensure that the plate is free of any 
remnants from previous use. (Hint: the Bradford method is a sensitive 
spectrophotometric procedure that is fully dependent upon samples’ color 
perception and subsequent light absorption. Colour presents as a result of a 
reaction between the protein assay dye reagent and the positively charged amine 
groups of proteins within a sample. Consequently, any debris on the well plate 
could interfere with light absorption readings.)  
8. Pipette 10 μL of each prepared standard solution and diluted sample into a 96–
well plate, in triplicate. 
9. Pipette 200 μL of stock protein assay dye reagent into each well. 
(Hint: use of a multi–channel pipette will save time at this step. However, 
individually loading each well with a single channel pipette will lead to greater 
consistency and superior results.) 
10. Allow a minimum of 2 minutes to pass for proper colour development to occur  
11. Insert the well plate into the spectrophotometer to generate absorbance readings. 
12. Open KC4™ data analysis software, and ensure that the reading parameters are 
set to absorbance. 
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13. Define the reading parameters by the following details: absorbance wavelength of 
595 nanometers, shaking intensity level of 3 and shaking duration of 5 seconds  
14. Proceed to read the absorbance of each standard and sample. 
15. Copy the absorbance readings into a Microsoft® Excel spreadsheet, and generate 
a standard curve by plotting known protein concentrations (BSA standard 
solutions) against their average absorbance readings. 
16. Outfit the standard curve with a polynomial trendline, and display the quadratic 
equation derived from this curve. 
17. Subtract the average absorbance reading of water for every sample, and calculate 
the unknown protein concentrations of all samples using the quadratic equation. 
(Hint: ensure that all protein concentrations are multiplied by 10 in order to obtain 
true quantifications, as sample homogenates were diluted 10–fold with DDH2O.) 
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Appendix D: Urea/Glycerol-PAGE and Immunoblotting 
 
 
Table D.1. UREA sample buffer; Add 30 volumes of Urea Sample Buffer per mg frozen 
tissue weight 
Chemical Name Volume 
8 M Urea Ultra Pure 1.83 ml 
Urea Gel Buffer 167 μL 
0.5 M DTT 40 μL 
Saturated Sucrose 100 μL 
0.2% Bromphenol Blue 40 μL 
0.4 M EDTA 1 μL 
 
 
 
 
 
Table D.2. Glycerol Gel preparation: 1. Sit for 10 minutes under vacuum; 2. add 113 uL 
of 10% APS and 20 uL of TEMED and mix by swirling; 3. Pour quickly into prepared 
minigel apparatus and insert 10 well combs (no stacking gel); 4. Gel should completely 
polymerize after 40 minutes. 
Chemical Name Volume 
H2O 1.83 ml 
Pure Glycerol 167 μL 
30% acrylamide/Bis 29:1 40 μL 
Urea Gel Buffer* 100 μL 
 
 
 
 
 
Table D.3. Urea Gel Buffer: Lower Buffer, 83 ml Urea Gel Buffer * . 917 ml H2O; Upper 
Buffer, 73.3 mg DTT / 53.3 mg thioglycholate / 200 ml of Lower Buffer. 
Chemical Name Volume 
Tris Base 54.8 g 
Glycine 40.0 g 
H2O Fill to 2L 
Adjust pH to 8.6 ± 0.1 
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Table D.4. Transfer Buffer 
Chemical Name Volume 
10 X Transfer Buffer* 100 mL 
100% Methanol 200 mL 
H2O 700 mL 
 
 
 
 
 
Table D.5. 10 X Transfer Buffer 
Components 
A. Glycine, 1153 g; 
Tris 242.3 g; 
Q.S. to 5 L with H2O 
 
B. SDS 40 g dissolved in  
3 L H2O 
 
MIX A + B 
 
 
 
 
 
 
Table D.6. TBST + Blocking Buffer 
Components 
52.6 g NaCl 
30 ml 2M Tris pH 7.5 
30 mL 10% Tween 
Q.S. to 6 liters with H2O. 
Blocking Buffer: 
5 g powdered milk (Carnation fat- free) in 100 mL 
TBST 
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Sample Preparation 
Sample denaturation 
 Add 0.5 mL Acetone-Based Protein Precipitation Solution (ABPS) to as many 
micocentrifuge tubes as there is samples, freeze in liquid N2.  
 Place frozen muscles into ABPS slurry and allow samples to come to room 
temperature, because this step is done at freezing temperature, all proteins in the 
sample using DTT and TCA with no enzyme activity  – no use of phosphatase or 
kinase inhibitors is used. 
Sample homogenization 
 Transfer muscle tissue into ground glass homogenizing tube, and add 0.5 mL of 
Water-Based Protein Precipitation Solution (WBPS), then homogenize sample 
with medium pressure. 
 Transfer homogenate to microcentrifuge tube and centrifuge at 2000 RPM for 3 
minutes 
 Discard supernatant and wash pellets with 500 uL of ether (3 times for 5 minutes) 
to remove TCA. Afterwards let residual ether evaporate from the tube for 5 
minutes. 
Resuspension 
 Add 300uL of urea sample buffer to each tube. Vortex, and check for blue color to 
ensure pH. If samples are yellow or green, add 5 uL of 2 M Tris Base (pH 11). 
 Add urea crystals to each sample until each sample is saturated by urea, then store 
at -80 C° until use. 
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Hand Casting of Polyacrylamide Gels 
 Add dH2O, glycerol, acrylamide, and urea gel buffer into vacuum flask, and 
stir for 10 minutes. 
 Draw 113 uL of 10% APS and 20 uL TEMED into pipettes, and add them to 
the gel solution in a 50 mL falcon tube.  
 Use transfer pipet to pour gel into casting plates, and insert combs into gel. 
 
Electrophoretic Separation 
Pre-Electrophoresis 
 Carefully remove combs, rinse wells with dH2O and Upper Buffer. 
 Pre-electrophorese at 400 V for 1 hour to force thioglycolate into the gel, and 
reduce residual APS that was used in polymerization (this prevents protein 
oxidation which will effect migration). 
 
Electrophoretic separation 
 Load 5-20 uL of each sample into wells, the urea and sucrose were added for 
increased density so the sample should layer in the well as a sharp band – 
amount to load depends on tissue source, so optimal amount needs to be 
determined. 
 Do not use the end wells as samples in the end well distort. 
 Electrophorese at 400 V for 85 minutes – Dye will run off gel but you can 
look at it during this step to ensure migration is normal.  
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Transferring Protein From Polyacrylamide Gel to Nitrocellulose Membrane 
Transferring 
 Use 8.5 x 7.0 cm pieces of nitrocellulose paper (0.45 mm pore size) 
 Prepare 1L of 1X transfer buffer from 10X stock solution 
 Pour 1X transfer bugger into trays in preparation for blotting sandwich 
 Disassemble electrode assembly, and remove gel cassettes. Separate plates using 
wedge. 
 Rinse gels gently in transfer buffer twice for 5 minutes to equilibrate, immerse 
nitrocellulose membrane in transfer buffer for 1 minute to wet and equilibrate. 
 With black side of the gel holder submerged in transfer buffer, assemble the blot 
sandwich in the following order: sponge, filter paper, gel, membrane, filter paper, 
and sponge. 
 Close cassette and lock, place into blotting module latch side up, with black side 
facing the black side of the module. Place magnetic stir bar in transfer tank and 
fill to ‘blotting’ line with added cooling packs. 
 Place lid on top of the cell, and run at 25 V for 1 hour  
Immunoblotting 
Blocking of Non-Specific Sites 
 Remove nitrocellulose membrane from the blot sandwich and transfer to a square 
petri dish 
 Wash the membrane in Tris-Buffered Saline with Tween-20 (TBST) three times 
for 10 minutes each 
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 Incubate with Blocking Buffer for 1 hour at room temperature to prevent non-
specific binding in a clean tray 
Primary Anti-Body Incubation 
 Wash membrane in TSBT twice, 10 minutes per wash 
 Add 1:7500 skMLCK polyclonal primary antibodies (provided by the lab of 
James Stull) to fresh blocking buffer in a clean tray, incubate overnight with 
rocking at 4°C. 
Secondary Anti-Body 
 Remove primary antibody and wash membrane in TBST (6 times for 10 minutes 
each) in a clean tray 
 Incubate with secondary antibody 1:10,000 dilution of Goat Anti-Rabbit IgG-
HRP in TBST for 1 hour in clean tray 
Detection of RLC 
 Wash membrane in TBST (6 times for 10 minutes each) 
 Make detection buffer using equal volumes of ECL prime luminol and oxidizing 
reagents (1 mL: 1 mL) 
 Rinse (manually) membrane in detection buffer for 2 minutes 
 Blot excess reagent from the corner of the membrane using a kim wipe, and place 
membrane in sheet protector. Roll to remove air bubbles and excess liquid 
 Expose for 6 minutes 
 Quantification of the RLC phosphorylation will be done using ImageStudio Lite, 
using signal analysis on blot images. Quantifying both the non-phosphorylated 
and phosphorylated band and then adding them together will give us the total 
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phosphorylation. Then, dividing out the phosphorylated band from the total will 
yield a % phosphorylation value. These values can then be compared against 
previous results from our lab to ensure that the methods were conducted properly. 
Appendix E: Experiments Determining Optimal Loading Volume and Band 
Characterization 
 
E.1.0 Determining Protein Quantification and Optimal Loading Volume 
 
  To quantify the amount of protein present in the Wildtype mouse EDL (whole 
muscle homogenate) a Bradford assay using BSA standard was conducted at 25°C. 
Analysis determined a protein concentration of 3.1 ug/uL, ensuring a coefficient of 
variation (CV%) of less than 5% across triplicate wells; the results of the Bradford 
analysis are presented in Table 9 as means ± standard deviation while the absorbance 
plot is presented in Figure 20. 
 
Table E.1. The absorbance readings of Bradford assay samples for Wildtype EDL at 
23°C 
 Well 1 Well 2 Well 3       Mean        CV% 
Standard Dilution     
1 0.910 0.891 0.973 0.925 ± 0.043 4.46 
0.5 0.789 0.787 0.787 0.788 ± 0.001 0.15 
0.25 0.561 0.588 0.532 0.560 ± 0.028 4.99 
0.125 0.423  0.451 0.422 ± 0.029 4.53 
0.05 0.45 0.458 0.434 0.448 ± 0.012 2.78 
0 0.27 0.281 0.278 0.276 ± 0.005 2.05 
Sample      
 0.583 0.643 0.636 0.621 ± 0.032  
Values are means ± SD (n = 1). CV%, denotes coefficient of variation calculated by dividing the 
sample mean – 0 from the standard deviation. Analysis was conducted on Wildtype whole 
muscle homogenate using the EDL, following the protocol outlined in Methods section.  
 
 
 
Figure E.1. Scatterplot of known sample (BSA standard) protein concentrations on the Y-axis and 
average absorbance readings on the X-axis. Results from Table E.1 indicate that Wildtype EDL Red Dot, 
represents mean score of 3 wells for each dilution of BSA.  
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 To determine the optimal protein loading volume, a loading profile using 
skMLCK-/- was performed to analyze the band density of non-phosphorylated myosin 
RLC across seven different volumes (Figure E.2.A; 5, 8, 10, 12, 14, 16, 18, and 20 uL); 
band intensity is plotted for each volume of sample in Figure E.2.B. Analysis determined 
that 10 uL was optimal for loading as the intensity was measurable, while western blots 
confirmed that wells were not overloaded at 10 uL. Thus, 10 uL was the highest volume 
of protein that could be loaded before crowning of wells. 
 
 
Figure E.2. (A) Urea/glycerol PAGE blot of non-phosphorylated myosin RLC band in skMLCK-/- 
muscles from a single sample. Protein was loaded from left to right at 5, 8, 10, 12, 14, 16, 18, and 20 uL. 
(B) Intensity of signal from the 5, 8, 10, 12, 14, and 16 uL bands presented above. The 18 and 20 uL bands 
have been omitted from the scatter plot because their over loading caused intensities of infinite value. 
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E.2.0 Characterizing Western Blots 
 
The goal of these experiments was to determine the effect of primary anti-body 
dilution on the observation of a non-specific (unknown) top band during RLC blots. 
Objectives of this work was to examine: 
 
 The band differences between skMLCK -/- muscles and Wildtype muscles, 
 The disappearance of the unknown band with lower dilutions of primary anti-
body, and  
 The effect of our secondary anti-body on its own. 
 Determine within-gel CV% of the same sample for reliability 
 
The top non-specific band associated with RLC blotting is common among labs using 
this technique. One difficulty with addressing the appearance of this band is that it does 
not always appear. Correspondence with Dr. Jim Stull has reveled 3 possible causes of 
this band as a product of primary anti-body’s polyclonal nature. Potential causes could 
be: 1) presence of smooth muscle RLC, 2) presence of cardiac RLC, and 3) over-use of 
primary antibody.  
 
Figure E.3. (A) Western blot for myosin RLC from the lab of Dr. Jim Stull presenting 3 primary bands: 
RLC, RLC-P, and an unidentified top band. These blots have been published as such in Ryder et al., 2007. 
(B) Western blot for myosin RLC from Dr. Vandenboom’s lab presenting the same 3-band migration 
pattern as those seen in Dr. Stull’s lab. Methods used in Dr. Vandenboom’s lab are the same as Dr. Stull. 
 
Presented here, an example of the unknown band from Dr. Stull’s lab (Figure A) 
and an example with stimulation, as seen in these Wildtype muscle samples. Furthermore 
it is important to note that the configuration of band arrangement can change. For 
example, the figures above show significant separation between the RLC band and the 
unknown band. However, both of these labs provide evidence to support that this band 
does not exclusively appear with great separation from the RLC band, and can also be 
found very tightly oriented (Figure C) to the RLC or not at all (Figure D).  
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Figure E.4. Western blots from Dr. Stull’s lab depicting a tight orientation of the upper and middle band 
(C) or the upper band not being present at all (D). 
 
Another characteristic of this band is that it is not only variable from gel to gel 
(Figure C and D), but also within gels (Figure E). Evidence from Dr. Vandenboom’s lab 
shows that the unknown band can appear in some, but not all wells, of the same sample. 
The figure below demonstrates this fact using the same sample of skMLCK-/- muscle (10 
uL) loaded into all wells. Well 3 shows the absence of this protein. 
 
Lastly, this band can be found in published literature. One recent example is from 
Ryder et al., (2007). At first look, the blots (shown in Figure F) seem to display only 2 
bands; RLC and RLC-P. However, a closer look reveals what appears to be the faint 
presence of the bottom of this unknown band. Comparing the band distance in the Ryder 
et al., (2007) image (Figure F) to the bands from Dr. Stull’s lab (Figure A) helps provide 
evidence that these bands have simply been cropped out of published work.  
 
 
Figure E.5. (A) Western blots of 10 uL resting skMLCK-/- muscles showing the within-blot variability of 
the unknown top-band Published work; (B) Published Western blot imaging of Wildtype RLC and RLC-P 
depicting the unknown top-band (Ryder et al., 2007). 
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Experiment 1:  skMLCK-/- vs. Wildtype Muscle 
 
To examine the basic band differences between fresh samples of skMLCK-/- 
muscle and Wildtype muscle, 10uL of fresh skMLCK-/- muscle was loaded (prepared that 
day) in 1 well; then loaded the same sample of 10uL Wildtype muscle in the remaining 7 
wells. This experiment shows us the migration difference between the non-
phosphorylated RLC band, and the phosphorylated RLC band.  
 
Note: The goal of this experiment was to also yield the non-specific band we often see above the 
RLC, however it was not present in this blot. This result is likely because of the use of fresh 
samples and not freezing in -80°C. 
 
 
 
Figure E.6. Western blot imaging of skMLCK-/- resting muscle in lane 1, followed by 10 uL of Wildtype 
phosphorylated muscle sample. This image clearly identifies the presence and location of the RLC-P band, 
as well as supports the use of 10uL loading as an optimal volume. 
 
Results 
 
Using the skMLCK-/- muscle as a control for the RLC band, we can identify a 
benchmark for where our protein of interest will appear. No unknown protein is observed 
in this blot, confirming its variability from blot to blot. Furthermore, the sample used in 
this blot was prepared fresh the day of running; however normally samples are frozen in -
80°C overnight before being run the next day. After this experiment, it may be that the 
freezing and thawing of protein samples may play a role in the appearance of this band. 
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Experiment 2:  Primary anti-body titration & Within-Gel Reliability 
 
 To try to help confirm if the presence of the unknown band was a product of over 
use of our primary anti-body, a titration was performed using three separate dilutions of 
skRLC polyclonal anti-body. Dot blots had determined that a 1:7,500 dilution of primary 
anti-body was optimal for resolution, thus this was the starting point for these 
experiments. This experiment was performed by running 8 wells of the same Wildtype 
muscle sample (10 uL). After protein transfer, the membrane was cut into lanes to 
separate the wells; each separate strip was subject to a different dilution of primary anti-
body (1:7,500; 1:10,500; 1:13,500). As a control for our secondary anti-body, a fourth 
strip did not undergo treatment with primary anti body.  
 
 
Figure E.7. Western blot imaging of stimulated Wildtype muscle on 4 separate membrane strips to asses 
the changes associated with increasing primary anti-body dilution; from left to right, 1:7500, 1:10,500; 
1:13,500, 0. The far right strip acts as a secondary anti-body control, ensuring there was no non-specific 
binding of the secondary. 
 
Results 
 
 Once again, our blot did not show clear indication of the unknown top band, and 
only depicts the RLC and RLC-P bands. A very slight appearance of the band may be 
most apparent in the 1:7,500 condition. One interpretation of this shadowing may be that 
the protein was overloaded, however the same sample showed no overloading in the 
previous gel as well as no overloading of the RLC-P band. Thus there is only some 
evidence that diluting the primary antibody may reduce this band. This experiment also 
verified that the secondary anti-body used in Dr. Vandenboom’s lab was not binding any 
protein not treated with the primary anti-body. This blot was also used to determine the 
reliability of within gel measurements of RLC phosphorylation by comparing the same 
sample run in 8 wells at 10 uL. Each sample showed 28% phosphorylation, confirming 
that within-gel variance of RLC phosphorylation is very low. 
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Experiment 3:  Over Homogenization and Sample Buffer Dilutions 
 
The final set of experiments was ran to test the hypothesis that the extra-band may 
be a result of 1) tissue over homogenization, 2) sample buffer over dilution, or 3) 
freeze/thaw effects. To this end, a Western was conducted with 2 different sample buffer 
dilutions (30:1 and 35:1), 2 different homogenizing regiments (20 twists and 50 twists), 
and re-running of samples from Experiment 1 to account for the effect of freezing a 
sample which had previously shown no extra band. 
 
 
Figure E.8. Western blot from Dr. Vandenboom’s lab depicting the effects of over homogenization, 
sample buffer dilution, and freeze/thaw effects. Samples from ‘last weeks samples’ were frozen for one 
week, and previous showed no presence of the undefined upper band  (See experiment 1). 
 
Results 
 
It appears that over homogenizing muscle doesn’t seem to add the extra band as a 
result of over breaking down protein. It is also apparent that increasing the sample buffer 
ratios does not add (or remove) the presence of the extra band. In addition, neither of 
these variables significantly altered phosphorylation measures.Lastly, it doesn’t seem that 
freeze thawing the previously used sample from last week added an extra band. However, 
it clearly deteriorated the sample. Moving forward our lab will plan to stress the 
importance of sample freshness. One particular observation concerning the presence of 
this band is that when it is present, it seems to bolsters the RLC P %. This could be 
because the extra band takes away from the RLC band and boosts the perception of 
myosin phosphorylation. 
 
 
  
138 
Conclusions 
 
 Evidence from multiple labs suggests several characteristics of the unknown 
band: 
o Does not always appear on blots 
o Does not always follow same migration distance from RLC 
o Does not change with stimulation 
o Can be either present or absent in the same sample of muscle tissue 
 
 There is some evidence to suggest that the unknown band is a product of under 
dilution with primary anti-body, however this has not been confirmed by our 
titration, as the band did not appear clearly enough. 
 
 Evidence from Dr. Vandenboom’s lab suggests that the use of fresh samples will 
help prevent the appearance of this band (avoid freezing and thawing of prepped 
sample).  
 
 One possible cause for band appearance may be over loading. There is saturation 
to the intensity measurement so an abundant protein density will not increase as 
the amount of protein is increased.  However, a much less abundant protein 
intensity will increase with increasing load because it is not saturated.  See 
following for example: 
 
 
 
 
Figure E.9. Protein loading curve illustrating how overloading proteins during gel 
electrophoresis will increase the likelihood of detection for proteins with a lower relative 
abundance (i.e., unidentified band). 
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Appendix F: Western Blots and Values 
 
 
 
 
Figure F.1. Western Blot images for data used in this project. RLC, denotes non-phosphorylated myosin 
RLC band; RLC-P, denotes mono-phosphorylated myosin RLC band. (A and B) Wildtype muscle samples 
from both the control and epinephrine condition, samples include both resting and stimulated at all time 
points; lanes 7 and 8 are skMLCK-/- samples. (C) Wildtype muscle samples from both the control and 
epinephrine condition, lanes 4,5,6 and 7 are over loaded/exposed. (D) Lanes 1-6 show Wildtype stimulated 
muscle samples at 5 and 480 seconds, while lanes 7 and 8 provide evidence of ~9% phosphorylation in 
skMLCK-/- values. (E) Image from experiment 3, Appendix E. (F and G) Wildtype muscle samples from 
both the control and epinephrine condition, samples include both resting and stimulated at all time points; 
lanes 7 and 8 are skMLCK-/- samples. 
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Figure F.2. . Western Blot images for data used in this project. RLC, denotes non-phosphorylated 
myosin RLC band; RLC-P, denotes mono-phosphorylated myosin RLC band. (H, I, and J) skMLCK-/- 
muscle samples from all conditions with both rest and stimulation. (K) Image from experiment 1, 
Appendix E. 
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Appendix G: Statistical Analysis  
 
Table G.1. Dependant variable ANOVA statistics for time, condition, and genotype, 
including F-score, degrees of freedom, and statistical significance. 
Absolute 
Concentric Force 
Mean Concentric Force  
Time 
Wildtype [F(13,91) = 26.58, P <0.0001] 
skMLCK-/- [F(13,91) = 11.75, P <0.0001] 
Condition 
Wildtype [F(1,7) = 60.77, P < 0.0001] 
skMLCK-/-  [F(1,7) = 27.10, P <0.0001] 
Genotype F(1,14) = 16.61, P < 0.0001] 
 
Peak Concentric Force 
 
Time 
Wildtype [F(13,91) = 29.35, P < 0.0001] 
skMLCK-/- [F(13,91) = 18.60, P < 0.0001] 
Condition 
Wildtype [F(1,7)=52.04, P = 0.0002] 
skMLCK-/-  [F(1,7)=17.30, P = 0.0042] 
Genotype [F(1,14) = 11.74, P = 0.0041 
Relative 
Concentric Force 
 
Mean Concentric Force 
 
Time Wildtype [F(13,91) = 34.99, P < 0.01] 
 skMLCK
-/- [F(13,91) = 13.22, P < 0.0001] 
Condition Wildtype [F(1,7) = 52.53, P < 0.0001] 
 skMLCK
-/- [F(13,91) = 13.22, P < 0.0001] 
Genotype [F(1,14)=16.35, P < 0.01] 
Myosin 
Phosphorylation Time 
 
Wildtype F(2,20)=29.66, P < 0.0001 
 
Condition 
 
Wildtype F(1,20)=0.995, P = 0.530 
 
 
 
